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Abstract
Nucleic acids play a critical role in many biological processes such as gene regulation and replication. The
development of small molecules that modulate nucleic acids with sequence or structure specificity would
provide new strategies for regulating disease states at the nucleic acid level. However, this remains challenging
mainly because of the nonspecific interactions between nucleic acids and small molecules. Three-way
junctions are critical structural elements of nucleic acids. They are present in many important targets such as
trinucleotide repeat junctions related to Huntington’s disease, a temperature sensor σ32 in E. coli, Dengue
virus, and HIV. Triptycene-derived small molecules have been shown to bind to nucleic acid three-way
junctions, resulting from their shape complementary. To develop a better understanding of designing
molecules for targeting different junctions, a rapid screening of triptycene-based small molecules is needed.
We envisioned that the installation of a linker at C9 position of the bicyclic core would allow for a rapid solid
phase diversification. To achieve this aim, we synthesized 9-substituted triptycene scaffolds by using two
different synthetic routes. The first synthetic route installed the linker from the amidation reaction between
carboxylic acid at C9 position of the triptycene and an amine linker, β-alanine ethyl ester. This new
9-substituted triptycene scaffold was then attached to a 2-chlorotrityl chloride resin for solid-phase
diversification. This enabled a rapid diversification and an easy purification of mono-, di-, and tri-peptide
triptycene derivatives. The binding affinities of these compounds were investigated towards a (CAG)�(CTG)
trinucleotide repeat junction. In the modified second synthetic route, we utilized a combined Heck coupling/
benzyne Diels-Alder strategy. This improved synthetic strategy reduced the number of steps and total reaction
times, increased the overall yield, improved solubilities of intermediates, and provided a new regioisomer that
was not observed in the previous synthesis. Through this investigation, we discovered new high-affinity lead
compounds towards a d(CAG)∙(CTG) trinucleotide repeat junction. In addition, we turned our attention to
σ32 mRNA, which contains a RNA three-way junction in E. coli. We demonstrated that triptycene-based
small molecules can modulate the heat shock response in E. coli.
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ABSTRACT 
 
TRIPTYCENE: A NUCLEIC ACID THREE-WAY JUNCTION BINDER SCAFFOLD 
 
Ina Yoon 
David M. Chenoweth 
 
Nucleic acids play a critical role in many biological processes such as gene 
regulation and replication. The development of small molecules that modulate nucleic 
acids with sequence or structure specificity would provide new strategies for regulating 
disease states at the nucleic acid level. However, this remains challenging mainly because 
of the nonspecific interactions between nucleic acids and small molecules. Three-way 
junctions are critical structural elements of nucleic acids. They are present in many 
important targets such as trinucleotide repeat junctions related to Huntington’s disease, a 
temperature sensor σ32 in E. coli, Dengue virus, and HIV. Triptycene-derived small 
molecules have been shown to bind to nucleic acid three-way junctions, resulting from 
their shape complementary. To develop a better understanding of designing molecules for 
targeting different junctions, a rapid screening of triptycene-based small molecules is 
needed. We envisioned that the installation of a linker at C9 position of the bicyclic core 
would allow for a rapid solid phase diversification. To achieve this aim, we synthesized 9-
substituted triptycene scaffolds by using two different synthetic routes. The first synthetic 
route installed the linker from the amidation reaction between carboxylic acid at C9 
position of the triptycene and an amine linker, β-alanine ethyl ester. This new 9-substituted 
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triptycene scaffold was then attached to a 2-chlorotrityl chloride resin for solid-phase 
diversification. This enabled a rapid diversification and an easy purification of mono-, di-, 
and tri-peptide triptycene derivatives. The binding affinities of these compounds were 
investigated towards a (CAG)·(CTG) trinucleotide repeat junction. In the modified second 
synthetic route, we utilized a combined Heck coupling/benzyne Diels-Alder strategy. This 
improved synthetic strategy reduced the number of steps and total reaction times, increased 
the overall yield, improved solubilities of intermediates, and provided a new regioisomer 
that was not observed in the previous synthesis. Through this investigation, we discovered 
new high-affinity lead compounds towards a d(CAG)∙(CTG) trinucleotide repeat junction. 
In addition, we turned our attention to σ32 mRNA, which contains a RNA three-way 
junction in E. coli. We demonstrated that triptycene-based small molecules can modulate 
the heat shock response in E. coli. 
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CHAPTER 1 : INTRODUCTION 
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1.1 Background 
Nucleic acids play a critical role in a number of biological processes. In 1958, 
Francis Crick first introduced the concept of the central dogma of molecular biology, which 
explains the flow of the genetic information from nucleic acids to proteins. He restated and 
extended this theory in his publication in 1970.1 According to the central dogma of 
molecular biology, deoxyribonucleic acid (DNA) carries the genetic information in most 
biological systems. DNA is transcribed into ribonucleic acid (RNA), which is then 
translated into protein (Figure 1.1). Although some exceptions such as reverse-
transcription from RNA to DNA have been found, genetic information generally flows 
from DNA to RNA to protein. 
 
 
Figure 1.1. Schematic representation of central dogma of molecular biology. 
Despite the importance of nucleic acids in crucial biological processes such as gene 
expression and regulation, they have been overlooked as drug targets. Instead, early drug 
discovery research focused on developing small molecules that target specific proteins, 
including enzymes and receptors.2-4 This trend was because structural information on 
nucleic acids was limited compared to that of proteins.4 Moreover, RNA was initially 
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considered as a passive intermediate in the process of converting DNA to proteins.5 In the 
1980s, the discovery of catalytic RNA such as ribozymes, further implicated the 
significance of RNA.6-11 Since then, there have been numerous achievements in nucleic 
acid crystallography, which provides new insights for the design of structure-based ligands 
targeting nucleic acids.4 Additionally, the Encyclopedia Of DNA Elements (ENCODE) 
project expanded our knowledge about previously unknown functions of non-coding 
RNA.3,5 With these findings, nucleic acids became interesting as under exploited drug 
targets. 
Targeting nucleic acids could provide a better way of treating disease states because 
nucleic acids are more closely related to gene expression and regulation than proteins are. 
Although protein targets have drawn much attention for several decades, a very limited 
number of such protein targets have been identified so far. Most such protein targets fall 
into only six families: G-protein-coupled receptors (GPCRs), serine/threonine and tyrosine 
protein kinases, zinc metallo-peptidases, serine proteases, nuclear hormone receptors and 
phosphodiesterases.12,13 Hangauer and coworkers estimated that about 85% of the human 
genome is transcribed into RNA, but only less than 3% of these transcripts is translated 
into protein.14 The remaining transcripts that do not code for proteins are non-coding RNAs, 
which are associated with a number of human diseases.15-17 Therefore, the development of 
small molecules that target nucleic acids could potentially lead to the discovery of 
unexplored drug targets linked to diseases that were previously undruggable at the protein 
level. 
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1.2 Nucleic Acids 
Nucleic acids are biomacromolecules and biopolymers of simple monomers called 
nucleotides. Levene discovered that nucleotides are composed of one of four nucleobases, 
a sugar, and a phosphate group (Figure 1.2).18 When the sugar is 2-deoxyribose, the 
biopolymer is called deoxyribonucleic acid (DNA), whereas when the sugar is ribose, the 
biopolymer is called ribonucleic acid (RNA). In addition to the difference in the type of 
sugar, the nucleobase thymine (T) in DNA is replaced by uracil (U) in RNA. Nucleobases 
are categorized into two groups, purines and pyrimidines: Adenine (A) and guanine (G) 
are purines, while cytosine (C), thymine (T), and uracil (U) are pyrimidines (Figure 1.2b). 
Each nucleotide is conjugated together through a phosphodiester bond between the 3’ and 
5’ carbon atoms in their sugar rings. When a new DNA strand is elongated, a nucleotide is 
added to the hydroxyl group of the 3’ carbon of the terminal nucleotide, providing a 5’ to 
3’ directionality to a nucleic acid strand (Figure 1.2c). 
DNA usually forms a double helix structure through Watson-Crick base pairing. 
Generally, adenine pairs with thymine, increasing stability through formation of two 
hydrogen bonds, whereas guanine pairs with cytosine, increasing stability through 
formation of three hydrogen bonds. In addition to hydrogen bonds, base-stacking 
interactions between nucleobases also stabilize the DNA double helix structure, such that 
the double helix structure is more favorable.  
In contrast to the DNA duplex structure, RNA is typically single stranded. The 
RNA single strand folds into different structural motifs such as bulges, loops, hairpins, and 
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junctions to increase its stability. Unlike DNA, many instances of non-canonical base 
pairing have been observed in RNA secondary structures. 
 
 
Figure 1.2. (a) Structures of 2-deoxyribose and ribose. (b) Structures of nucleobases: adenine (A), 
guanine (G), cytosine (C), thymine (T), and uracil (U). (c) Linkage between nucleotides through a 
phosphate group. 
 
1.3 DNA Targeting Small Molecules 
DNA has been considered as a fundamental target for small molecules in medicinal 
chemistry because it is a source of the genetic information in biological systems. Despite a 
number of important roles of DNA in many disease-associated processes, only a handful 
of small molecules that target DNA have been discovered and studied due to the lack of 
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structural information on DNA. However, with the tremendous progress in structural 
biology and nucleic acid chemistry, interactions between nucleic acids and their ligands 
have begun to be unveiled. Interactions between small molecules and nucleic acids can be 
classified into five categories: covalent bond formation, minor groove binding, major 
groove binding, intercalating, and multimode binding.4,19 It is also worth noting that the 
majority of DNA-binding small molecules have aromatic ring systems. 
1.3.1 Covalent Binders 
The most common interaction between small molecules and DNA occurs via 
covalent bond formation, which is an irreversible modification on DNA. A small molecule 
usually forms an adduct with DNA to change the conformation of DNA. This 
conformational change interrupts the function of DNA to inhibit the transcription or 
replication processes.19 In general, covalently binding molecules have poor selectivity and 
exhibit high toxicity against normal cells. The most well-known example of a covalent 
binder is cisplatin (Figure 1.3). Although cisplatin generally causes severe side effects such 
as vomiting and nausea, this drug was approved by the FDA in1978 to treat several types 
of cancer. The mechanism of action of cisplatin is the formation of cross-links between 
two adjacent bases, either GG or GA (1,2-intrastrand adduct), or between two guanines 
separated by another base (1,3-intrastrand adduct).20 More examples of small molecules 
that covalently bind to DNA are shown in Figure 1.3. 
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Figure 1.3. Small molecules that target DNA through covalent bond formation. 
 
1.3.2 Minor Groove Binders 
Small molecules not only form permanent covalent bonds with DNA strands, they 
also interact with the minor grooves of DNA strands. Initially, minor groove-binding small 
molecules preferentially bound to AT-rich regions. Because minor groove binding offers 
the highest sequence specificity between DNA and small molecule ligands, minor groove 
binders have great potential as new therapeutics.4 Typical structural features of minor 
groove binders are heterocyclic dications and polyamides.4,19 Chemical structures of minor 
groove binders such as berenil, DAPI, netropsin, Hoechst 33258 are shown in Figure 1.4. 
Interestingly, the unusual 8-ring cyclic Py-Im polyamide-α was shown to bind to a DNA 
duplex, widening the minor groove. This finding supported the concept of allosteric 
changes to DNA conformation by minor groove binders.19  
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Figure 1.4. Small molecules that target DNA through binding to minor grooves. 
 
1.3.3 Major Groove Binders 
Compared to minor groove binders, very few major groove binders have been 
explored because of the requirement of much larger molecules. Due to their size and their 
hydrophilic and hydrophobic substructures, carbohydrates bind to the DNA major groove 
as well as to the DNA minor groove.4,19 Examples of small molecules that bind to DNA 
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major groove are summarized in Figure 1.5. Two neocarzinostatin derivatives, 
neocarzinostatin-gb and neocarzinostatin-glu, were used as ligands to the DNA duplex. 
Interestingly, neocarzinostatin-gb binds to the major groove, but neocarzinostatin-glu 
binds to the minor groove.21,22  
 
 
Figure 1.5. Small molecules that target DNA through binding to major grooves. 
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1.3.4 Intercalators 
The fourth type of interaction between small molecules and DNA is called 
intercalation. Planar aromatic rings of intercalators are usually inserted between DNA base 
pairs and interrupt DNA replication and transcription.4,19 In general, intercalators bind to 
the DNA duplex with high association constants of 105 – 1011 M-1.4 However, the 
specificity of intercalation is low, making most intercalators toxic to normal cells. Some 
interesting intercalators are shown in Figure 1.6. Daunomycin, which is also known as 
Cerubidine, is an effective drug for treating certain types of leukemia. Furthermore, 
adriamycin, which has two extra hydroxyl groups relative to daunomycin, is also an 
anticancer drug.23 Ditercalinium, which is a dimer of pyridocarbozole, binds to the DNA 
duplex via a bis-intercalation mode and induces DNA repair processes to treat cancer. 
1.3.5 Multimode Binders 
Multimode binders have been designed to increase the affinity as well as the 
specificity toward DNA by combining more than two binding modes. In 2009, the Weisz 
group reported a pyrrolo[2,1-c][1,4]benzodiazepine-benzimidazole hybrid (PBD-BIMZ, 
Figure 1.7) as a multimode binder.24 This molecule is shown to bind to the DNA duplex 
through covalent bond formation to a guanine base at its exocyclic 2-amino group in 
double-helical DNA. At the same time, PBD-BIMZ also shows a minor groove binding 
interaction with the DNA duplex. A year later, the Weisz group developed another 
multimode binder, PBD-naphthalimide conjugate (Figure 1.7), which binds to 
d(AACAATTGTT)2.25  
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Figure 1.6. Small molecules that target DNA through intercalation. 
 
 
Figure 1.7. Small molecules that target DNA through multimode binding patterns. 
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1.4 Three-way Junctions 
Three-way junctions are important high-order structures found in nucleic acids. 
These junction motifs are present in both prokaryotes and eukaryotes. Three-way junctions 
are typically Y-shaped and contain a hydrophobic space at the center of the junction (Figure 
1.8A).26-29 DNA three-way junctions are involved in a number of biological processes such 
as replication and recombination.30 In addition, they appear in the trinucleotide repeat 
expansions related to neurodegenerative diseases as well as in some DNA virus genomes. 
RNA three-way junctions are present in a number of biologically important targets, 
including telomerase RNA, σ32 mRNA in E. coli, the internal ribosome entry site (IRES) 
domain of the hepatitis C virus (HCV), the hammerhead ribozyme, a flavivirus 3’-UTR 
junction in Zika and Dengue viruses, and HIV RRE (Figure 1.8).31-40  
The junction present in σ32 mRNA regulates the heat shock response in E. coli. At 
30 °C, the ribosomal binding site of σ32 mRNA is blocked near a perfectly paired three-
way junction (PP-3WJ), inhibiting translation. At 42 °C, the mRNA structure is 
destabilized and the ribosomal binding site is exposed, allowing for efficient translation of 
σ32 protein.35,36,41-45 The PP-3WJ controls the thermodynamic stability of this critical 
regulatory switch.46-50 Modulation of this regulatory element in the heat shock response in 
E. coli with small molecules would lead to a development of a novel way to treat bacterial 
diseases.  
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Figure 1.8. (A) A schematic representation of three-way junctions and a few examples of 
interesting biological targets that contain three-way junctions. (B) A secondary structure of 
biologically relevant three-way junctions. 
Trinucleotide repeats are associated with a large number (>30) of inherited human 
muscular and neurological diseases.33,34 The trinucleotide repeat tract length is dynamic 
and often correlates with disease severity; tracts with few repeats are commonplace in the 
non-affected. Long triplet repeats are prone to further expansion as opposed to contraction 
and are predisposed to generational transmission.33,34 Structural features in these RNAs 
may determine if proteins are recruited for repair.33,34,51,52 Ligands that bind to these 
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junctions may therefore modulate repair outcomes via protein recruitment. Shifting the 
equilibrium of the repeat expansion to a branched form could translate into a therapeutic 
benefit by modulating repair pathways or protein binding. Further, Week and Busan 
recently discovered that a three-way junction is a unique structural feature that appears in 
Huntington’s disease-associated mRNA.53 Targeting three-way junctions already present 
in trinucleotide repeat sequences has the potential to discriminate between healthy and 
disease-inducing alleles, perhaps leading to novel treatment strategies for this class of 
neurodegenerative disease. 
The flavivirus 3’-UTR has an interesting multi-bulged junction. The flavivirus 
genus contains many clinically important human pathogens such as Zika, Dengue, West 
Nile, yellow fever, and Japanese encephalitis viruses. These viruses affect more than 50 
million people around the world every year.38,39,54-56 The flavivirus family has a conserved 
long and highly structured 3’-UTR that regulates replication and generates a functional 
non-coding RNA, subgenomic flavivirus RNA (sfRNA). A unique three-way junction 
structure of the SL-II domain in 3’-UTR prevents complete degradation of viral gRNA by 
stalling XRN1 reactivity. This structure also generates sfRNA, which represses two 
pathways of viral mRNA degradation.38,39,54-56 Modulation of the three-way junction in the 
highly organized SL-II domains would decrease the production of sfRNA and may lead to 
drugs that treat infections caused by viruses in the flavivirus family. 
The HIV RRE RNA, which contains two unique three-way junctions, is another 
important target for small molecules.57 The Rev protein interaction with the structured RRE 
is important in the late phase of HIV replication. Binding of the triptycene ligand to three-
way junctions in the RRE region could interfere with the binding of Rev and inhibit the 
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export of full length HIV RNA to the cytoplasm. To date, there have been no attempts to 
target these critical junctions and represents a completely new concept for modulation of 
the RRE and HIV RNA. 
1.5 Triptycene 
Triptycene (1; 9,10-dihydro-9,10-[1,2]benzenoanthracene) is the first and smallest 
molecule in an iptycene family, which is a class of aromatic compounds composed of 
arenes fused to a bicyclo[2,2,2]octane scaffold.58-60 In 1981, the new concept of iptycenes 
was proposed by Hart to generalize triptycene-related small molecules.61 The number of 
separated arene units are shown as a prefix. For example, triptycenes (1) have three 
separated arene units, pentiptycenes (2) have five separated arene units, and so on (Figure 
1.9). Due to the unique rigid structural features of the iptycene family, they have special 
electrochemical and photochemical properties, making these compounds useful in a wide 
range of applications in diverse research areas.58-60  
 
 
Figure 1.9. Structures of triptycene (1) and pentiptycene (2). 
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1.5.1 Synthesis of Triptycenes 
Triptycene, which has three phenyl rings fused to a bicyclo core scaffold, was first 
synthesized and introduced by Barlett and co-workers in 1942. They proposed its name 
‘triptycene’ because “the shape of this ring system suggests the triptych of antiquity, which 
was a book with three leaves hinged on a common axis.”62 The first synthesis of triptycene 
by Barlett is shown in Scheme 1.1.62 The Diels-Alder reaction between anthracene (3) and 
1,4-benzoquinone yielded compound 4. The rearrangement of 4 with hydrobromic acid and 
glacial acetic acid resulted in hydroquinone 5, which was then oxidized to quinone 6. The 
dioxime 7 was prepared from two hours of heating to reflux in presence of 6 and 
hydroxylamine hydrochloride in ethanol. The dioxime 7 was then converted into the 
diamine 8. A deamination reaction of 8 led to a mixture of mono-, and di-chlorotriptycene 
9. Finally, the removal of the chlorine group from the ring with potassium hydroxide, 
palladium on calcium carbonate, and hydrazine hydrate in alcohol was successful to 
synthesize triptycene 1. In 1959, a simple and direct synthetic route was reported by Craig 
and Wilcox.63 They reduced Diels-Alder adduct 4 with LiAlH4 or NaBH4 and heated the 
crude product to reflux in ethanolic hydrochloric acid. Chromatography of the products on 
acid alumina provided triptycene in 15% overall yield. 
A one-step synthesis of triptycene from anthracene and benzyne in 28% isolated 
yield was achieved by Wittig and Ludwig in 1956 (Table 1.1, entry 1).64 Inspired from 
their work, various benzyne precursors have been used to synthesize triptycene in higher 
yield under mild conditions (Table 1.1). In 1960, Stiles and Miller reported that the 
decomposition of benzenediazonium-2-carboxylate leading to benzyne produced  
17 
 
Scheme 1.1. The first synthesis of triptycene by Barlett and co-workers. 
 
 
triptycene in 30% yield (Table 1.1, entry 2).65 Three years later, Friedman and Logullo 
prepared triptycene from anthracene and anthranilic acid in the presence of amyl nitrite 
again via benzyne (Table 1.1, entry 3).66 Kitamura and Yamane dramatically increased the 
yield to 86% by using a new benzyne precursor, (phenyl)[o-(trimethylsilyl)phenyl] 
iodonium triflate (Table 1.1, entry 5).68,69 In addition, Himeshima and coworkers reported 
a fluorine-induced benzyne precursor, o-trimethylsilylphenyl triflate (10) to provide an 
efficient and mild generation of benzyne for organic reactions.70  
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Table 1.1. Synthesis of triptycene with various benzyne precursors.58  
 
 
Scheme 1.2. A structure of a fluorine-induced benzyne precursor. 
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1.5.2 Applications of Triptycenes 
Triptycenes have been extensively studied and used in a number of research 
areas.58-60 In a recent microreview, Jiang and Chen summarized the synthesis and 
applications of triptycene and pentiptycene derivatives in six main categories: molecular 
machines, molecular balances, catalysts, materials chemistry, crystal engineering, and 
host–guest chemistry.60 Triptycene derivatives were utilized in molecular gear systems 
starting in 1981.71,72 In addition, triptycene derivatives were employed as potential 
molecular rotors in macroscopic compasses, gyroscopes, molecular dials, molecular 
brakes, molecular ratchets and more.73-83 Pioneered by Ōki in the 1970s, a number of 
triptycene derivatives have been used as promising molecular balances to study non-
covalent interactions such as CH⸱⸱⸱O, π-π, and oxygen⸱⸱⸱arene interactions.84-91 Next, 
triptycene-based complexes have been used as catalysts in organic reactions such as the 
palladium-catalyzed Suzuki coupling.92-98 Recently, Leung and coworkers synthesized a 
triptycene-based monophosphine ligand and used the ligand for palladium-catalyzed 
Suzuki-Miyaura cross-coupling and asymmetric hydrosilylation.98 The triptycene scaffold 
has attracted a great deal of attention from material scientists due to the unusual internal 
free volume (IFV), which was first introduced and defined by Swager in 2001.99 IFV exists 
because of the inefficient packing of triptycenes, which prevent them from obtaining fully 
co-planar molecular orientations. Inspired by his work, many triptycene derivatives have 
been synthesized and utilized in material chemistry and crystal engineering.100-110 Lastly, 
Chen developed a number of triptycene-derived hosts for potential uses in molecular 
recognition and molecular assemblies.111-124 The synthesis and applications of triptycene-
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derived hosts were summarized in Chen’s recent microreview published in 2010.60 Most 
recently, Chen reported triptyene-based chiral macrocyclic hosts, which have a helical 
chiral cavity at the center of the molecule, for enantioselective recognition of chiral guests 
containing a trimethylamino group.124  
 
 
Figure 1.10. Structures of triptycene-baesd chiral macrocyclic hosts for enantioselective 
recognition of chiral guests containing a trimethylamino group.124  
Although triptycenes have been used in a variety of applications in diverse fields 
of study, biological applications of triptycenes are seldom studied.125,126 In 2014, Barros 
and Chenoweth first reported the recognition of the nucleic acid three-way junction using 
triptycene-based molecules.127 In their study, triptycene-based small molecules 
discriminate DNA three-way junctions (3WJ) from double-stranded DNA (ds DNA). They 
explained the key structural features of the triptycene scaffold needed to achieve specific 
recognition of a three-way junction. First, triptycene has a three-fold symmetric structure 
that matches with the symmetry of the central helical region of the nucleic acid three-way 
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junction. In addition, the triptycene scaffold has similar dimensions to the center of the 
three-way junction, allowing triptycene-based molecules to fit perfectly into the junction 
interface (Figure 1.11). The discontinuous π-surface area of the triptycene also plays an 
important role in minimizing classical intercalative binding modes, which generally cause 
nonspecific nucleic acid binding. A number of biophysical methods including UV thermal 
melting, circular dichroism (CD), gel shift, and fluorescence quenching experiments were 
employed to study the junction recognition of triptycene-based molecules. In addition, 
Barros and Chenoweth reported the cytotoxicity and cellular uptake of these molecules in 
two human ovarian carcinoma cell lines.127 They also reported the modulation of a 
(CAG)·(CTG) trinucleotide repeat junction using triptycene-based small molecules in 
2015.128 These research findings open a door to new applications of triptycenes in 
biomolecular recognition. 
 
 
Figure 1.11. Model of triptycene located at a central binding pocket of a model RNA three-way 
junction. 
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1.6 Overview of Dissertation 
In this dissertation, we expanded the previous study of molecular recognition of 
nucleic acid three-way junctions by using triptycene-based molecules. 
In Chapter 2, the synthesis of 9-substituted tripycene derivatives will be described. 
Starting from a commercially available material, 9-anthraldehyde, we synthesized the 9-
substituted triptycene scaffold. The aldehyde at the C9 position of anthracene was then 
converted to carboxylic acid at the C9 position of triptycene. This carboxylic acid was 
coupled to a beta-alanine ethyl ester linker via MsCl activation to extend the length of the 
linker. The linker at the C9 position of triptycene enables attachment to a solid support 
such as a polymer-bound resin. Attachment to the resin permits rapid diversification of 
triptycene scaffold by a solid-phase synthesis. We synthesized mono-, di-, and tri-
functionalized triptycene derivatives via peptide coupling reactions on the resin-bound 
triptycene scaffold. The binding properties of the synthesized triptycene derivatives were 
then evaluated by using a (CAG)·(CTG) trinucleotide repeat junction as a model system. 
In Chapter 3, we describe an improved synthetic route to the 9-substituted 
triptycene scaffold. The number of steps and the reaction times were reduced, compared to 
the previous MsCl activation strategy. In addition, the solubility of the intermediates was 
greatly improved to enable a large-scale synthesis. The immobilization technique described 
in Chapter 2 was also applied to this new triptycene scaffold for solid-phase diversification. 
A potent lead compound towards a (CAG)·(CTG) trinucleotide repeat junction was 
discovered with Kd value of 90 nM. 
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In Chapter 4, we demonstrate the modulation of an RNA three-way junction, σ32 
mRNA in E. coli, with triptycene derivatives. In this investigation, we used a model system 
to study the thermal stabilization of the three-way junctions in the presence of triptycenes. 
Then, we expanded our investigation to include in vivo assays. A reporter assay was 
designed to monitor the expression level of the σ32 protein in E. coli at different 
temperatures in the presence or absence of triptycene derivatives. In the presence of lysine 
and arginine derivatized triptycenes, the fluorescence intensity decreased, indicating the 
suppression or delay of the heat shock response in E. coli at high temperature. 
1.7 Bibliography 
1 Crick, F. Nature 1970, 227, 561. 
2 Imming, P.; Sinning, C.; Meyer, A. Nat. Rev. Drug Discov. 2006, 5, 821. 
3 Velagapudi, S. P.; Cameron, M. D.; Haga, C. L.; Rosenberg, L. H.; Lafitte, M.; 
Duckett, D. R.; Phinney, D. G.; Disney, M. D. Proc. Natl. Acad. Sci. U. S. A. 2016, 
113, 5898. 
4 Sheng, J.; Gan, J.; Huang, Z. Med. Res. Rev. 2013, 33, 1119. 
5 van Wolfswinkel, J. C.; Ketting, R. F. J. Cell Sci. 2010, 123, 1825. 
6 Cech, T. R.; Zaug, A. J.; Grabowski, P. J. Cell 1981, 27, 487. 
7 Cech, T. R. Proc. Natl. Acad. Sci. USA 1986, 83, 4360. 
8 Cech, T. R. Science 1987, 236, 1532. 
9 Cech, T. R. Science 2000, 289, 878. 
10 Cech, T. R. Annu. Rev. Biochem. 1990, 59, 543. 
11 Athota, R. R.; Radhakrishnan, T. M. Biochem. Educ. 1991, 19, 72. 
12 Hopkins, A. L.; Groom, C. R. Nat. Rev. Drug Discov. 2002, 1, 727. 
24 
 
13 Bull, S. C.; Doig, A. J. PLoS One 2015, 10, e0117955. 
14 Hangauer, M. J.; Vaughn, I. W.; McManus, M. T. PLoS Genet. 2013, 9, e1003569. 
15 Connelly, C. M.; Moon, M. H.; Schneekloth, J. S. Cell Chem. Biol. 2016, 23, 
1077. 
16 Cheetham, S. W.; Gruhl, F.; Mattick, J. S.; Dinger, M. E. Br. J. Cancer 2013, 108, 
2419. 
17 Esteller, M. Nat. Rev. Genet. 2011, 12, 861. 
18 Levene, P. A. J. Biol. Chem. 1917, 40, 415. 
19 Wang, M.; Yu, Y.; Liang, C.; Lu, A.; Zhang, G. Int. J. Mol. Sci. 2016, 17, 779. 
20 Jamieson, E. R.; Lippard, S. J. Chem. Rev. 1999, 99, 2467. 
21 Gao, X.; Stassinopoulos, A.; Ji, J.; Kwon, Y.; Bare, S.; Goldberg, I. H. 
Biochemistry 2002, 41, 5131. 
22 Kwon, Y.; Xi, Z.; Kappen, L. S.; Goldberg, I. H.; Gao, X. Biochemistry 2003, 42, 
1186. 
23 Frederick, C. A.; Williams, L. D.; Ughetto, G.; van der Marel, G. A.; van Boom, J. 
H.; Rich, A.; Wang, A. H. Biochemistry 1990, 29, 2538. 
24 Rettig, M.; Weingarth, M.; Langel, W.; Kamal, A.; Kumar, P. P.; Weisz, K. 
Biochemistry 2009, 48, 12223. 
25 Rettig, M.; Langel, W.; Kamal, A.; Weisz, K. Org. Biomol. Chem. 2010, 8, 3179. 
26 Altona, C. J. Mol. Biol. 1996, 263, 568. 
27 LESCOUTE, A. RNA 2006, 12, 83. 
28 Lilley, D. M. Q. Rev. Biophys. 2000, 33, 109. 
29 Duckett, D. R.; Lilley, D. M. J. EMBO J. 1990, 9, 1659. 
30 Singleton, M. R.; Scaife, S.; Wigley, D. B. Cell 2001, 107, 79. 
31 Bhat, P.; Gnanasundram, S. V.; Mani, P.; Ray, P. S.; Sarkar, D. P.; Das, S. RNA 
Biol. 2012, 9, 1110. 
32 Hermann, T.; Westhof, E. J. Mol. Biol. 1998, 276, 903. 
25 
 
33 Castel, A. L.; Cleary, J. D.; Pearson, C. E. Nat. Rev. Mol. Cell Biol. 2010, 11, 165. 
34 Mirkin, S. M. Nature 2007, 447, 932. 
35 Grossman, A. D.; Straus, D. B.; Walter, W. A. Genes Dev. 1987, 1, 179. 
36 Guisbert, E.; Yura, T.; Rhodius, V. A.; Gross, C. A. Microbiol. Mol. Biol. Rev. 
2008, 72, 545. 
37 Kortmann, J.; Narberhaus, F. Nat. Rev. Microbiol. 2012, 10, 255. 
38 Funk, A.; Truong, K.; Nagasaki, T.; Torres, S.; Floden, N.; Balmori Melian, E.; 
Edmonds, J.; Dong, H.; Shi, P.-Y.; Khromykh, A. A. J. Virol. 2010, 84, 11407. 
39 Gritsun, T. S.; Gould, E. A. Adv. Virus Res. 2007, 69, 203. 
40 Sztuba-Solinska, J.; Shenoy, S. R.; Gareiss, P.; Krumpe, L. R. H.; Le Grice, S. F. 
J.; O’Keefe, B. R.; Schneekloth, J. S. J. Am. Chem. Soc. 2014, 136, 8402. 
41 Straus, D. B.; Walter, W. a; Gross, C. a. Genes Dev. 1989, 3, 2003. 
42 Straus, D.; Walter, W.; Gross, C. A. Genes Dev. 1990, 4, 2202. 
43 Straus, D. B.; Walter, W. A.; Gross, C. A. Nature 1987, 329, 348. 
44 Zhou, Y. N.; Kusukawa, N.; Erickson, J. W.; Gross, C. A.; Yura, T. J. Bacteriol. 
1988, 170, 3640. 
45 Zhou, Y. N.; Gross, C. A. J. Bacteriol. 1992, 174, 7128. 
46 Yano, R.; Nagai, H.; Shiba, K.; Yura, T. J. Bacteriol. 1990, 172, 2124. 
47 Yuzawa, H.; Nagai, H.; Mori, H.; Yura, T. Nucleic Acids Res. 1993, 21, 5449. 
48 Nagai, H.; Yuzawa, H.; Yura, T. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 10515. 
49 Morita, M.; Kanemori, M.; Yanagi, H.; Yura, T. J. Bacteriol. 1999, 181, 401. 
50 Morita, M. T.; Tanaka, Y.; Kodama, T. S.; Kyogoku, Y.; Yanagi, H.; Yura, T. 
Genes Dev. 1999, 13, 655. 
51 Cleary, J. D.; Tomé, S.; López Castel, A.; Panigrahi, G. B.; Foiry, L.; Hagerman, 
K. A.; Sroka, H.; Chitayat, D.; Gourdon, G.; Pearson, C. E. Nat. Struct. Mol. Biol. 
2010, 17, 1079. 
52 Cleary, J. D.; Nichol, K.; Wang, Y.-H.; Pearson, C. E. Nat. Genet. 2002, 31, 37. 
26 
 
53 Busan, S.; Weeks, K. M. Biochemistry 2013, 52, 8219. 
54 Clarke, B. D.; Roby, J. A.; Slonchak, A.; Khromykh, A. A. Virus Res. 2015, 206, 
53. 
55 Roby, J. A.; Pijlman, G. P.; Wilusz, J.; Khromykh, A. A. Viruses 2014, 6, 404. 
56 Paranjape, S. M.; Harris, E. J. Biol. Chem. 2007, 282, 30497. 
57 Bai, Y.; Tambe, A.; Zhou, K.; Doudna, J. A. Elife 2014, 3, e03656. 
58 Zhao, L.; Li, Z.; Wirth, T. Chem. Lett. 2010, 39, 658. 
59 Ma, Y.-X.; Meng, Z.; Chen, C.-F. Synlett 2015, 26, 6. 
60 Jiang, Y.; Chen, C. F. European J. Org. Chem. 2011, 32, 6377. 
61 Hart, H.; Shamouilian, S.; Takehira, Y. J. Org. Chem. 1981, 46, 4427. 
62 Bartlett, P. D.; Ryan, M. J.; Cohen, S. G. J. Am. Chem. Soc. 1942, 64, 2649. 
63 Craig, A. C.; Wilcox, C. F. J. Org. Chem. 1959, 24, 1619. 
64 Wittig, G.; Ludwig, R. Angew. Chem. 1956, 68, 40. 
65 Stiles, M.; Miller, R. G. J. Am. Chem. Soc. 1960, 82, 3802. 
66 Friedman, L.; Logullo, F. M. J. Am. Chem. Soc. 1963, 85, 1549. 
67 Cadogan, J. I. G.; Hall, J. K. A.; Sharp, J. T. J. Chem. Soc. C 1967, 1860. 
68 Kitamura, T.; Yamane, M. J. Chem. Soc., Chem. Commun. 1995, 983. 
69 Kitamura, T.; Yamane, M.; Inoue, K.; Todaka, M.; Fukatsu, N.; Meng, Z.; 
Fujiwara, Y. J. Am. Chem. Soc. 1999, 121, 11674. 
70 Himeshima, Y.; Sonoda, T.; Kobayashi, H. Chem. Lett. 1983, 12, 1211. 
71 Cozzi, F.; Guenzi, A.; Johnson, C. A.; Mislow, K.; Hounshell, W. D.; Blount, J. F. 
J. Am. Chem. Soc 1981, 103, 957. 
72 Kawada, Y.; Iwamura, H. J. Am. Chem. Soc. 1981, 103, 958. 
73 Kelly, T. R.; De Silva, H.; Silva, R. A. Nature 1999, 401, 150. 
74 Godinez, C. E.; Zepeda, G.; Garcia-garibay, M. A. J. Am. Chem. Soc. 2002, 124, 
4701. 
27 
 
75 Godinez, C. E.; Zepeda, G.; Mortko, C. J.; Dang, H.; Garcia-Garibay, M. A. J. 
Org. Chem. 2004, 69, 1652. 
76 Kelly, T. R. Acc. Chem. Res. 2001, 34, 514. 
77 Nikitin, K.; Müller-Bunz, H.; Ortin, Y.; McGlinchey, M. J. Org. Biomol. Chem. 
2007, 5, 1952. 
78 Kelly, T. R.; Silva, R. A.; De Silva, H.; Jasmin, S.; Zhao, Y. J. Am. Chem. Soc. 
2000, 122, 6935. 
79 Nikitin, K.; Müller-Bunz, H.; Ortin, Y.; Muldoon, J.; McGlinchey, M. J. J. Am. 
Chem. Soc. 2010, 132, 17617. 
80 Kelly, T. R.; Tellitu, I.; Sestelo, J. P. Angew. Chem. Int. Ed. Engl. 1997, 36, 1866. 
81 Nikitin, K.; Müller-Bunz, H.; Ortin, Y.; McGlinchey, M. J. Chem. - A Eur. J. 
2009, 15, 1836. 
82 Harrington, L. E.; Cahill, L. S.; McGlinchey, M. J. Organometallics 2004, 23, 
2884. 
83 Kelly, T. R.; Cai, X.; Damkaci, F.; Panicker, S. B.; Tu, B.; Bushell, S. M.; 
Cornella, I.; Piggott, M. J.; Salives, R.; Cavero, M.; Zhao, Y.; Jasmin, S. J. Am. 
Chem. Soc. 2007, 129, 376. 
84 Mati, I. K.; Cockroft, S. L. Chem. Soc. Rev. 2010, 39, 4195. 
85 Ōki, M. Acc. Chem. Res. 1990, 23, 351. 
86 Ōki, M.; Izumi, G.; Yamamoto, G.; Nakamura, N. Chem. Lett. 1980, 213. 
87 Ōki, M. Angew. Chemie Int. Ed. English 1976, 15, 87. 
88 Gung, B. W.; Emenike, B. U.; Lewis, M.; Kirschbaum, K. Chem. - A Eur. J. 2010, 
16, 12357. 
89 Gung, B. W.; Xue, X.; Reich, H. J. J. Org. Chem 2005, 70, 3641. 
90 Gung, B. W.; Patel, M.; Xue, X.; Trans, P. 2005, No. 19, 10532. 
91 Gung, B. W.; Zou, Y.; Xu, Z.; Amicangelo, J. C.; Irwin, D. G.; Ma, S.; Zhou, H. 
C. J. Org. Chem. 2008, 73, 689. 
92 Azerraf, C.; Cohen, S.; Gelman, D. Inorg. Chem. 2006, 45, 7010. 
93 Bini, L.; Müller, C.; Wilting, J.; Von Chrzanowski, L.; Spek, A. L.; Vogt, D. J. 
28 
 
Am. Chem. Soc. 2007, 129, 12622. 
94 Grossman, O.; Gelman, D. Org. Lett. 2006, 8, 1189. 
95 Grossman, O.; Azerraf, C.; Gelman, D. Organometallics 2006, 25, 375. 
96 Tauchert, M. E.; Warth, D. C. M.; Braun, S. M.; Gruber, I.; Ziesak, A.; Rominger, 
F.; Hofmann, P. Organometallics 2011, 30, 2790. 
97 Azerraf, C.; Gelman, D. Organometallics 2009, 28, 6578. 
98 Leung, F. K.-C.; Ishiwari, F.; Shoji, Y.; Nishikawa, T.; Takeda, R.; Nagata, Y.; 
Suginome, M.; Uozumi, Y.; Yamada, Y. M. A.; Fukushima, T. ACS Omega 2017, 
2, 1930. 
99 Long, T. M.; Swager, T. M. Adv. Mater. 2001, 13, 601. 
100 Swager, T. M. Acc. Chem. Res. 2008, 41, 1181. 
101 Chong, J. H.; MacLachlan, M. J. Chem. Soc. Rev. 2009, 38, 3301. 
102 Long, T. M.; Swager, T. M. J. Am. Chem. Soc. 2002, 124, 3826. 
103 Hilton, C. L.; Jamison, C. R.; Zane, H. K.; King, B. T. J. Org. Chem. 2009, 74, 
405. 
104 Pei, B.-J.; Chan, W.-H.; Lee, A. W. M. J. Org. Chem. 2010, 75, 7332. 
105 Chen, Z.; Swager, T. M. Macromolecules 2008, 41, 6880. 
106 Jiang, Y.; Chen, C. F. Synlett 2010, 11, 1679. 
107 Weidman, J. R.; Guo, R. Ind. Eng. Chem. Res. 2017, 56, 4220. 
108 Chong, J. H.; Maclachlan, M. J. Inorg. Chem. 2006, 45, 1442. 
109 Yang, J.-S.; Liu, C.-P.; Lin, B.-C.; Tu, C.-W.; Lee, G.-H. J. Org. Chem. 2002, 67, 
7343. 
110 Chong, J. H.; MacLachlan, M. J. J. Org. Chem. 2007, 72, 8683. 
111 Han, T.; Chen, C. F. Org. Lett. 2007, 9, 4207. 
112 Meng, Z.; Xiang, J.-F.; Chen, C.-F. Chem. Sci. 2014, 5, 1520. 
113 Han, Y.; Meng, Z.; Chen, C.-F. Chem. Commun. 2016, 52, 590. 
29 
 
114 Guo, J. Bin; Xiang, J. F.; Chen, C. F. European J. Org. Chem. 2010, 5056. 
115 Zhu, X.-Z.; Chen, C.-F. J. Am. Chem. Soc. 2005, 127, 13158. 
116 Han, T.; Zong, Q.; Chen, C. J. Org. Chem. 2007, 72, 3108. 
117 Han, T.; Chen, C. F. J. Org. Chem. 2007, 72, 7287. 
118 Zhang, C.; Chen, C.-F. J. Org. Chem. 2007, 72, 3880. 
119 Han, T.; Chen, C. F. J. Org. Chem. 2008, 73, 7735. 
120 Jiang, Y.; Cao, J.; Zhao, J. M.; Xiang, J. F.; Chen, C.-F. J. Org. Chem. 2010, 75, 
1767. 
121 Zong, Q.-S.; Chen, C.-F. Org. Lett. 2006, 8, 211. 
122 Han, T.; Chen, C. F. Org. Lett. 2006, 8, 1069. 
123 Zong, Q.-S.; Zhang, C.; Chen, C.-F. Org. Lett. 2006, 8, 1859. 
124 Zhang, G.-W.; Li, P.-F.; Meng, Z.; Wang, H.-X.; Han, Y.; Chen, C.-F. Angew. 
Chem., Int. Ed. 2016, 55, 5304. 
125 Perchellet, E. M.; Wang, Y.; Weber, R. L.; Lou, K.; Hua, D. H.; Perchellet, J. P. 
Anticancer Drugs 2004, 15, 929. 
126 Perchellet, E. M.; Wang, Y.; Lou, K.; Zhao, H.; Battina, S. K.; Hua, D. H.; 
Perchellet, J.-P. H. Anticancer Res. 2007, 27, 3259. 
127 Barros, S. A.; Chenoweth, D. M. Angew. Chem., Int. Ed. 2014, 53, 13746. 
128 Barros, S. A.; Chenoweth, D. M. Chem. Sci. 2015, 6, 4752. 
 
  
30 
 
 
 
 
 
 
 
 
CHAPTER 2 : SYNTHESIS OF 9-SUBSTITUTED TRIPTYCENE 
BUILDING BLOCKS FOR SOLID-PHASE DIVERSIFICATION AND 
NUCLEIC ACID JUNCTION TARGETING 
 
 
 
 
 
 
 
 
 
 
 
This work was done in collaboration with Sung-Eun Suh, and Dr. Stephanie A. Barros. 
 
Adapted with permission from Yoon, I.; Suh, S.-E.; Barros, S. A.; Chenoweth, D. M. Org. Lett., 
2016, 18, 1096-1099. Copyright 2016 American Chemical Society. 
  
31 
 
2.1 Introduction 
Nucleic acid junctions play important roles in many biological events. Three-way 
junctions (3WJs) have diverse architectures and are found in DNA and RNA, where they 
often serve as important structural elements.1-3 Several small molecules are known to bind 
to nucleic acid junctions. However, these molecules often lack specificity, leading to 
binding of various structures.4-7 Recently, we reported a new class of three-way junction 
stabilizers based on the triptycene scaffold.8 The unique shape and 3-fold symmetry of 
triptycene allows for binding to nucleic acid three-way junctions. We also reported 
triptycene derivatives that bind to a d(CAG)∙(CTG) trinucleotide repeat junction.9  
 
 
Figure 2.1. Strategy for triptycene solid-phase diversification. 
Efficient strategies for triptycene diversification are needed to accelerate the 
discovery of new nucleic acid junction binders with enhanced specificity and binding 
properties. Triptycene building blocks that are amenable to immobilization on a solid 
support would allow for rapid diversification and compound library construction (Figure 
2.1).10,11 To immobilize triptycene, we designed and synthesized a 9-substituted derivative 
that provides a point of attachment at the bridgehead, maintaining the C3 symmetry.12,13 
Although triptycene has been extensively modified for use in materials chemistry 
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applications,14,15 functionalization at the C9-position of triptycene has rarely been 
reported.16  
A carboxylic acid was chosen for functionalization at the C9 tertiary carbon of 
triptycene, due to its versatility of conversion into other functional groups, such as 
aldehyde, haloalkane, ester, and amide. The carboxylic acid group may also be removed 
via decarboxylation at a later stage. More importantly, the carboxylic acid group has been 
extensively employed for directed C-H bond functionalization reactions, which could 
prove valuable during future triptycene diversification efforts.17-20  
 
 
Figure 2.2. Retrosynthesis of key building block A. FGI = functional group interconversion; ox. = 
oxidation, red. = reduction, DA = Diels-Alder reaction. 
Our synthetic plan (Figure 2.2) relies on reduction of the nitro groups on precursor 
B to yield building block A. Further disconnection of the amide bond at the bridgehead 
position affords carboxylic acid C. A β-alanine ethyl ester was coupled to the carboxylic 
acid on C. O-Directed nitration was envisioned to regioselectively build three nitro groups 
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onto triptycene D. In addition to nitration, simultaneous oxidation of the alcohol of D to 
the desired bridgehead carboxylic acid was anticipated. Next, disconnection at C9 and C10 
affords benzyne and anthracene E precursors, which could be assembled via a Diels-Alder 
reaction. Precursor E was prepared by reduction of aldehyde F. Early-stage 
functionalization of triptycene at C9 would provide an efficient route to a triptycene 
building block suitable for solid-phase immobilization and further diversification. 
2.2 Results and Discussion 
Commercially available anthracene-9-carbaldehyde 1 was employed as a starting 
material. Reduction of 1 using sodium borohydride afforded anthracen-9-ylmethanol 2 in 
96% yield within 1 h (Scheme 2.1). Prior to the addition of the Kobayashi benzyne 
precursor, the primary alcohol was protected with a MOM group to prevent electrophilic 
attack by benzyne. The Diels-Alder reaction between 3 and benzyne, which was generated 
in situ from 2-(trimethylsilyl)phenyltrifluoromethanesulfonate and cesium fluoride, led to 
the efficient formation of triptycene 4 in high yield. 
Treatment of 4 with nitric acid resulted in nitration of the aromatic rings. During 
the nitration reaction, the protecting group on the alcohol was simultaneously deprotected 
and oxidized to the carboxylic acid, providing 6a along with two other isomers 6b and 6c. 
The nitrated triptycene isomers proved inseparable by silica gel chromatography. Acid-
catalyzed esterification of the crude mixture provided ester isomers 5a-c, which were 
separated via silica gel chromatography. The structures of ester isomers 5a-c were 
confirmed by two-dimensional NMR spectroscopy, HMBC, and HSQC. Single crystals of 
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5a were grown in CHCl3/CH2Cl2/CH3OH, and the structure was determined by X-ray 
crystallography (Scheme 2.1). Following separation of each isomer, saponification was 
performed to convert the ester to a carboxylic acid for coupling to an amine linker. Nitration 
on the α-carbon was not observed due to its higher electronegativity compared to that of β-
carbons.20  
Scheme 2.1. Approach toward the synthesis of 9-substituted trifunctionalized triptycenes 6a−c and 
X-ray Crystal Structure of 5a. 
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To investigate the O-directing effect observed during nitration and to further reduce 
the number of undesired side products, compound 8, containing a carboxylic acid at the C9 
position, was prepared by deprotection of 4 followed by KMnO4 oxidation (Figure 2.3). 
Compounds 4, 7, and 8 were treated with excess nitric acid at 80 °C for 24 h, and the crude 
mixtures were analyzed by HPLC using 9,10-diphenylanthrancene as an internal standard. 
HPLC analysis demonstrated that nitration of 8 led to fewer side products compared to 
nitration of 4 and 7 (See Figure 2.6 ~ Figure 2.9 in section 2.4 Material and Methods for 
HPLC chromatograms). 
 
 
Figure 2.3. Composition of 6a−c from the nitration of compounds 4, 7, and 8. 
Interestingly, nitration of 7 produced little of desired products 6a-c. The 
composition of 6a and 6c significantly changed compared to that from the nitration of 4 
and 8, and the overall yield increased for the nitration of 8. Attempts were made to increase 
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the proportion of 6a over that of the other isomers. The highest ratio of 6a to 6b achieved 
treating nitric acid on triptycene was 0.33.21-25 The introduction of a carboxylic acid at the 
C9 position of triptycene significantly increased the ratio of 6a to 6b to 0.81. These 
observations are consistent with the carboxylic acid functioning as a directing group during 
the nitration reaction. 
Table 2.1. Reaction conditions for amide-bond formation at the linker position. 
 
 
Isomer 6a was chosen for further elaboration due to its 3-fold symmetry, which is 
complementary to that of nucleic acid 3WJs. To extend the length of the linker at the 9-
position, several standard reaction conditions for amide bond formation were examined. 
However, the amidation reaction proved recalcitrant, and all attempted conditions resulted 
in unreacted starting material (Table 2.1, entries 2-4). The coupling of 9-
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triptycenecarboxylic acid derivatives with EDC has been previously reported.26 However, 
this method was not reproducible using 6a as the starting material (Table 2.1, entry 1). Our 
results suggested that the sterically hindered environment around the carboxylic acid 
prevents coupling of amines under standard conditions, possible due in part to the bulky 
active ester intermediates. After a comprehensive literature search, we were inspired by 
Nicolaou’s use of methanesulfonyl chloride (MsCl) in the total synthesis of the CP 
molecules to overcome limitations of a difficult Arndt-Eistert homologation on sterically 
encumbered carboxylic acids.27 Triethylamine and MsCl were added to 6a followed by 
addition of β-alanine ethyl ester hydrochloride, which was pretreated with triethylamine at 
0 °C. After being warmed to room temperature, 9 was synthesized in 48% yield (Table 2.1, 
entry 7). However, complete conversion of the starting material was not achieved under 
these conditions. To drive the reaction to completion, the base was changed to pyridine, 
which is less sterically hindered and allows for access to the carboxylic acid near the 
bridge-head position. The solvent was also changed to dichloromethane due to solubility 
issues. These changes led to completion of the reaction within 1 h after warming to room 
temperature and a substantial increase in the yield to 92% (Table 2.1, entry 5). A decrease 
in the equivalence of MsCl and pyridine decreased the yield to 61% (Table 2.1, entry 6). 
Among the various amide bond-forming reaction conditions tested on triptycene 6a, only 
the mesylation route afforded the desired product in high yield. 
Pd/C-catalyzed hydrogenation of 9 led to reduction of the three nitro groups to 
afford triaminotriptycene 10. Next, the free amines were protected with Fmoc groups by 
treatment with Fmoc chloride and pyridine. The linker ester group was hydrolyzed in the 
presence of sulfuric acid and water to produce acid 12. The free carboxylate of fully 
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protected building block 12 allowed for attachment to 2-chlorotriyl chloride resin, which 
is compatible with Fmoc deprotection chemistry (Scheme 2.2). After attachment to resin, 
the Fmoc groups were deprotected using 20% piperidine in dimethylformamide to generate 
the free amines. The corresponding Fmoc-protected amino acid was preactivated with 
HATU and N,N-diisopropylethylamine (DIPEA) and added to the deprotected triptycene 
on resin. L-Histidine, L-lysine, and L-asparagine were selected for attachment to the 
triptycene arms. The deprotection and coupling steps were repeated until the desired 
sequence of amino acids was achieved (Scheme 2.3a). Once the desired peptide was 
synthesized on solid phase, the triptycene derivatives were cleaved from the resin with 
simultaneous deprotection of the amino acid side chain protecting groups by treatment with 
Scheme 2.2. Synthesis of SPPS precursor 12 and loading on 2-chlorotrityl chloride resin. 
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a cleavage solution (9:1:1 trifluoroacetic acid (TFA)/2,2,2-trifluoroethanol 
(TFE)/dichloromethane). Asparagine, which was coupled at the N-terminus, required 
longer cleavage times due to the slow deprotection rate of the trityl group close to the amino 
group (Scheme 2.3b).28,29 Each compound was purified by preparative reversed-phase 
HPLC and analyzed by analytical HPLC and MALDI-MS. 
Scheme 2.3. (a) Solid-phase peptide synthesis of 9-substituted triptycene on 2-chlorotrityl chloride 
resin. (b) Cleavage from the resin to generate triptycene derivatives 17−19. 
 
 
*Deprotection required 12 h for triptycene 19. CT = 2-chlorotrityl chloride resin. 
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Figure 2.4. Graphical representation of the fluorescence-quenching 3WJ assay. 
Table 2.2. Dissociation constants of triptycenes 17−20. Note: Synthesis of triptycene 20 lacking a 
bridgehead substituent has been previously reported.9  
 
 
Triptycenes 17-19 were evaluated for binding towards a d(CAG)∙(CTG) 
trinucleotide repeat junction using a previously developed fluorescence-quenching 
experiment.9 The binding of triptycenes 17-19 were compared to a previously reported 
triptycene that binds to the junction. The previously reported junction binder (20) is 
analogous to 17 but lacks the linker at the 9-position. A d(CAG)∙(CTG) repeat junction 
was labeled with a fluorophore (FAM) and a quencher (IowaBlk). This labeled 3WJ was 
preincubated with a 10 bp inhibitor (I10) strand that is complementary to the junction. 
Hybridization of the inhibitor strand to the junction results in an open form, leading to an 
increase in fluorescence (Figure 2.4). Triptycenes 17-20 were added to the preincubated 
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fluorescent form. Binding of the triptycenes leads to displacement of I10 and reformation 
of the 3WJ, resulting in a decrease in fluorescence. The Kd value for triptycene 17 was 
determined to be 8.38 μM and exhibited a slight decrease in binding compared to that of 
triptycene 20 (i.e., Kd value of 1.76 μM). Triptycenes 18 and 19, containing di- or 
tripeptides substituents, exhibited enhanced binding affinity toward the junction compared 
to that of 20 with Kd values of 0.27 and 0.46 μM, respectively (Table 2.2). The presence of 
lysine appears to play an important role in binding to the junction and will be investigated 
in future studies. 
2.3 Conclusions 
In summary, we have developed a synthetic approach for preparing new 9-
substituted triptycene building blocks. This approach enables solid-phase diversification of 
triptycene. During the synthesis, O-directed nitration was observed from the MOM 
protected primary alcohol (4), primary alcohol (7), and carboxylic acid (8) at the C9 
position of triptycene. These results indicated that the carboxylic group increased the ratio 
of nitration on β-carbons toward the linker position, pointing to a possible carboxylic acid 
directing effect. In addition, a key amide bond formation was achieved on a sterically 
hindered and geometrically fixed tertiary carboxylic acid using a MsCl activation strategy. 
This tactic may be regarded as a general strategy toward functionalization of extremely 
sterically encumbered tertiary carboxylic acids. For diversification of the new triptycene 
building block, three amino acids were utilized including histidine, lysine, and asparagine 
to produce trisubstituted triptycenes 17-19. The binding ability of the synthesized 
42 
 
triptycene derivatives toward a d(CAG)∙(CTG) trinucleotide repeat junction was evaluated, 
and triptycenes 18 and 19 exhibited better binding affinity to the junction compared to that 
of a previously reported triptycene with no linker (20). This new synthetic strategy provides 
rapid and efficient access to triptycene building blocks, enabling high-throughput 
diversification for rapid evaluation of potential junction binders and other medicinal 
chemistry targets. 
2.4 Material and Methods 
General information 
All commercial reagents and solvents were used as received. 9-
anthracenecarboxaldehyde, sodium borohydride, N,N-diisopropylethylamine (DIPEA), 
chloromethyl methyl ether, beta-Alanine ethyl ester hydrochloride, Fmoc chloride, 
palladium on activated carbon, cesium fluoride, 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate, and nitric acid from Aldrich, 1-[bis(dimethylamino)-
methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxide hexafluorophosphate (HATU) 
from Oakwood Products, Inc., 2-chlorotrityl chloride resin from Advanced ChemTech, 
chloroform-d, methylene chloride-d2, dimethylsulfoxide-d6, and acetone-d6 from 
Cambridge Isotope Laboratories Inc. were purchased. HPLC-purified TNR DNA 3WJ 
oligo modified with a 5’-FAM and a 3’-IowaBlack (5’-(FAM)-GCGGAGCAG-
CCCTTGGGCAGCACCTTGGTGCTGCTCCGC-(IowaBlk)-3’) and DNA inhibitor 10 
(5’-GCTGCTCCGC-3’) were purchased from Integrated DNA Technologies (IDT). 
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Flash column chromatography was performed using Silicycle silica gel (55−65 Å 
pore diameter). Thinlayer chromatography was performed on Sorbent Technologies silica 
plates (250 μm thickness). Proton nuclear magnetic resonance spectra (1H NMR) and 
Carbon nuclear magnetic resonance (13C NMR) spectra were recorded on a Bruker DMX 
500. High-resolution mass spectrometry analysis was obtained by Dr. Rakesh Kohli at the 
University of Pennsylvania’s Mass Spectrometry Service Center on a Waters LC-TOF 
mass spectrometer (model LCT-XE Premier) using electrospray ionization. High-
performance liquid chromatography (HPLC) chromatograms were recorded and 
triptycenes 17-19 was purified on JASCO HPLC (Easton, MD) equipped with a 
Phenomenx (Torrance, CA) column (Analytical: Luna 5μ C18(2) 100A; 250 x 4.60 mm, 5 
μm Semi-prep: 5μ C18(2) 100A; 250 x 10.00 mm, 5 μm) using aqueous (H2O + 0.1% 
CF3CO2H) and organic (CH3CN) phases. Matrix-assisted laser desorption ionization 
(MALDI) mass spectra were recorded on a Bruker Ultraflex III MALDI-TOF-TOF mass 
spectrometer (Billerica, MA) using α-cyano-4-hydroxycinnamic acid (CHCA). 
Fluorescence measurements were obtained on a Tecan M1000 plate reader (Mannedorf, 
Switzerland).  
 
Experimental procedures 
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anthracen-9-ylmethanol (2): To 4.9 g (23.76 mmol) of anthracene-9-carbaldehyde (1) in 
THF (50 mL) was added 1.35g (35.64 mmol) of NaBH4. The mixture was stirred for 1 h at 
25 °C. The mixture was poured into water (400 mL) resulting in a yellow precipitate. The 
yellow solid was filtered off, washed thoroughly with water, and dried. (4.7 g, 96 % isolated 
yield).30  
1H NMR (500 MHz, CDCl3) δ 8.46 (s, 1H), 8.40 (d, 2H, J = 8.8 Hz), 8.02 (d, 2H, J = 8.4 
Hz), 7.59-7.53 (m, 2H), 7.52-7.46 (m, 2H), 5.65 (s, 2H). 
 
 
9-((methoxymethoxy)methyl)anthracene (3): To 354 mg (1.7 mmol) of anthracen-9-
ylmethanol (2) in CH2Cl2 was added 1.76 mL (10.2 mmol) of N,N-diisopropylethylamine 
at 0 °C. After stirring for 30 min, 0.4 mL (5.1 mmol) of chloromethylmethyl ether was 
added to this solution at 0 °C. The mixture was stirred for 10 min, warmed to 25 °C, and 
stirred for 18 h. Saturated NH4Cl (aq) solution was added to the reaction. The organic layer 
was extracted from the solution, dried with anhydrous sodium sulfate, concentrated in 
vacuo, and purified by column chromatography using ethyl acetate/hexanes (4%) as the 
eluent to give 391 mg of 3 (391 mg, 91 % isolated yield). 
Physical Property: Pale yellow solid, m.p. = 80-81 °C. 
TLC: Rf = 0.52 (silica gel, 25% ethyl acetate/hexanes). 
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1H NMR (500 MHz, CDCl3) δ 8.53 (d, 2H, J = 8.8 Hz), 8.47 (s, 1H), 8.04 (d, 2H, J = 8.4 
Hz), 7.68-7.62 (m, 2H), 7.58-7.51 (m, 2H), 5.67 (s, 2H), 4.90 (s, 2H), 3.61 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 131.6, 131.3, 129.2, 128.7, 128.4, 126.4, 125.1, 124.4, 
95.7, 61.1, 55.8. 
IR (neat): 1733, 1446, 1265, 1147, 1093, 1061, 1029, 934, 914, 891, 731, 703, 640 cm-1. 
HRMS (ESI) calculated for C17H16NaO2+ [M+Na]+ 275.1043, found 275.1055. 
 
 
9-((methoxymethoxy)methyl)-9,10-dihydro-9,10-[1,2]benzenoanthracene (4): To a 
vial was added 384 mg (1.52 mmol) of 3, 907 mg (3.04 mmol) of 2-(trimethylsilyl)phe-nyl 
trifluoromethanesulfonate, 693 mg (4.56 mmol) of CsF, and 2.5 mL of acetonitrile at 25 
°C. The solution was heated to 80 °C and stirred for 2 h under Argon gas. After the reaction 
was completed, Saturated NH4Cl (aq) solution and ethyl acetate were added to the reaction 
mixture. The organic layer was extracted from the solution, dried with anhydrous sodium 
sulfate, concentrated in vacuo, and washed with hexanes. The crude mixture was then 
purified by column chromatography using dichloromethane (100%) as the eluent to give 4 
(464 mg, 93 % isolated yield). 
Physical Property: Pale yellow solid, m.p. = 197-198 °C. 
TLC: Rf = 0.39 (silica gel, 25% ethyl acetate/hexanes). 
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1H NMR (500 MHz, CDCl3) δ 7.62-7.46 (m, 6H), 7.18-7.09 (m, 6H), 5.52 (s, 1H), 5.27 (s, 
2H), 5.22 (s, 2H), 3.80 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 146.7, 144.8, 125.3, 125.2, 123.6, 122.4, 98.3, 67.0, 56.8, 
54.5, 53.2. 
IR (neat): 1375, 1337, 1265, 1183, 1035, 951, 945, 824, 736, 647, 634 cm-1. 
HRMS (ESI) calculated for C23H20NaO2+ [M+Na]+ 351.1356, found 351.1356. 
 
 
methyl trinitro-9,10-[1,2]benzenoanthracene-9(10H)-carboxylate (5a-5c): To a round 
bottom flask was added 3.97 g (12.1 mmol) of 4 and 50 mL of concentrated nitric acid at 
25 °C. The solution was heated to 80 °C and stirred for 24 h. After the reaction was 
complete, water was added to the solution. The solution was neutralized with K2CO3 and 
re-acidified with 1M HCl. Ethyl acetate was added to the solution and the organic layer 
was extracted from the solution. The combined organic solution was dried with anhydrous 
sodium sulfate, and concentrated in vacuo. To the crude mixture was added 40 mg of 
H2SO4 and 100 mL of anhydrous methanol. The solution was stirred under reflux for 24 h. 
After the reaction was completed, the solution was cooled, extracted with ethyl acetate, 
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dried with anhydrous sodium sulfate, and then concentrated in vacuo. The crude mixture 
of 5a-5c was then purified using column chromatography. The composition of each isomer 
was determined by HPLC analysis. 
 
 
methyl 2,7,15-trinitro-9,10-[1,2]benzenoanthracene-9(10H)-carboxylate (5a): 
Physical Property: White solid, m.p. = 282-283 ˚C. 
TLC: Rf = 0.41 (silica gel, 50% ethyl acetate/hexanes). 
1H NMR (500 MHz, CDCl3) δ 8.64 (d, 3H, J = 2.1 Hz), 8.08 (dd, 3H, J = 8.2, 2.2 Hz), 7.64 
(d, 3H, J = 8.2 Hz), 5.77 (s, 1H), 4.43 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ .167.9, 148.9, 146.3, 143.1, 124.9, 122.9, 120.1, 61.4, 53.8, 
53.6. 
IR (neat): 2924, 1746, 1522, 1455, 1340, 1301, 1274, 1250, 1214, 1166, 1025, 903 cm-1. 
HRMS (ESI) calculated for C22H14N3O8+ [M+H]+, no peak matched the calculated exact 
mass. Hydrolysis of the ester to carboxylic acid 6a was required to obtain the HRMS. See 
HRMS data on acid 6a. 
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methyl (9s,10r)-2,6,15-trinitro-9,10-[1,2]benzenoanthracene-9(10H)-carboxylate 
(5b): 
Physical Property: White Solid, m.p. = 163-164 ˚C. 
TLC: Rf = 0.73 (silica gel, 50% ethyl acetate/hexanes). 
1H NMR (500 MHz, CDCl3) δ 8.63 (d, 2H, J = 2.0 Hz), 8.33 (d, 1H, J = 2.0 Hz), 8.04 (dd, 
2H, J = 8.1, 2.0 Hz), 7.99 (dd, 1H, J = 8.5, 2.0 Hz), 7.89 (d, 1H , J = 8.5 Hz), 7.70 (d, 2H, 
J = 8.1 Hz), 5.89 (s, 1H), 4.40 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 168.1, 149.6, 147.9, 146.2, 144.4, 142.7, 125.4, 125.1, 
122.9, 122.1, 120.1, 119.4, 61.6, 53.5, 53.4. 
IR (neat): 2924, 1743, 1519, 1455, 1341, 1297, 1214, 1165, 1071, 1024, 892 cm-1. 
HRMS (ESI) calculated for C22H14N3O8+ [M+H]+, no peak matched the calculated exact 
mass. Hydrolysis of the ester to carboxylic acid 6b was required to obtain the HRMS. See 
HRMS data on acid 6b. 
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methyl (9r,10s)-2,6,14-trinitro-9,10-[1,2]benzenoanthracene-9(10H)-carboxylate 
(5c): 
Physical Property: White Solid, m.p. = 161-162 °C. 
TLC: Rf = 0.81 (silica gel, 50% ethyl acetate/hexanes). 
1H NMR (500 MHz, CDCl3) δ 8.65 (d, 1H, J = 2.2 Hz), 8.33 (d, 2H, J = 2.3 Hz), 8.09 (dd, 
1H, J = 8.2, 2.2 Hz), 8.05 (dd, 2H, J = 8.6, 2.3 Hz), 7.93 (d, 2H, J = 8.6 Hz), 7.67 (d, 1H, J 
= 8.2 Hz), 5.80 (s, 1H), 4.37 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 168.1, 149.8, 147.4, 146.24, 146.21, 144.7, 142.3, 125.5, 
124.9, 122.9, 122.1, 120.3, 119.3, 61.9, 53.4, 53.3. 
IR (neat): 2924, 1744, 1598, 1458, 1438, 1342, 1254, 1165, 1023 cm-1. 
HRMS (ESI) calculated for C22H14N3O8+ [M+H]+, no peak matched the calculated exact 
mass. Hydrolysis of the ester to carboxylic acid 6c was required to obtain the HRMS. See 
HRMS data on acid 6c. 
 
 
General procedure for preparation of trinitro-9,10-[1,2]benzenoanthracene-9(10H)-
carboxylic acid (6a-6c):To 1 eq of 5a (or 5b, 5c) dissolved in p-dioxane was added 3 eq 
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of 1M NaOH (aq) and heated to 60 °C for 24 h. After the reaction was completed, the 
solution was neutralized and acidified with 1N HCl. Ethyl acetate was added to the solution 
and the organic layer was extracted from the solution. The combined organic layer was 
washed with NH4Cl (aq) and brine. The organic layer was dried with anhydrous sodium 
sulfate, and concentrated in vacuo to give 6a (or 6b, 6c) in quantitative yield. 
 
 
2,7,15-trinitro-9,10-[1,2]benzenoanthracene-9(10H)-carboxylic acid (6a): 
Physical Property: Pale yellow solid, m.p. = 358-359 °C. 
TLC: Rf = 0.43 (silica gel, 100% ethyl acetate). 
1H NMR (500 MHz, (CD3)2CO) δ 9.23 (s, 3H), 7.96 (dd, 3H, J = 8.1, 1.9 Hz), 7.74 (d, 3H, 
8.1 Hz), 6.21 (s, 1H). 
13C NMR (125 MHz, (CD3)2CO) δ 171.3, 151.3, 147.5, 146.1, 124.6, 121.8, 121.4, 63.7, 
53.4. 
IR (neat): 2924, 1592, 1518, 1341, 1262, 1092, 1069, 1023, 903 cm-1. 
HRMS (ESI) calculated for C21H10N3O8- [M-H]- 432.0473, found 432.0457. 
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(9s,10r)-2,6,15-trinitro-9,10-[1,2]benzenoanthracene-9(10H)-carboxylic acid (6b): 
Physical Property: Pale yellow solid, m.p. = 265-266 °C. 
TLC: Rf = 0.23 (silica gel, 100% ethyl acetate). 
1H NMR (500 MHz, (CD3)2CO) δ 9.29 (d, 2H, J = 2.2 Hz), 8.54 (d, 1H, J = 8.3 Hz), 8.36 
(d, 1H, J = 2.2 Hz), 8.01 (dd, 2H, J = 8.1, 2.2 Hz), 7.88 (d, 1H, J = 8.1 Hz), 7.81 (d, 2H, J 
= 8.1 Hz), 6.28 (s, 1H). 
13C NMR (125 MHz, (CD3)2CO) δ 171.2, 152.5, 151.7, 146.8, 146.0, 145.9, 145.5, 127.3, 
124.6, 121.8, 121.4, 121.1, 118.6, 63.7, 53.1. 
IR (neat): 2921, 1737, 1593, 1524, 1462, 1377, 1344, 1260, 1093 cm-1. 
HRMS (ESI) calculated for C21H10N3O8- [M-H]- 432.0473, found 432.0462. 
 
 
(9r,10s)-2,6,14-trinitro-9,10-[1,2]benzenoanthracene-9(10H)-carboxylic acid (6c): 
Physical Property: White solid, m.p. = 202-203 ˚C. 
TLC: Rf = 0.03 (silica gel, 100% ethyl acetate). 
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1H NMR (500 MHz, (CD3)2CO) δ 8.92 (s, 1H), 8.49 (s, 2H), 8.23 (d, 2H, J = 8.6 Hz), 8.15-
8.06 (m, 3H), 7.95 (d, 1H, 8.2 Hz), 6.47 (s, 1H). 
13C NMR (125 MHz, (CD3)2CO) δ 168.6, 151.1, 148.2, 146.2, 146.1, 145.7, 142.9, 125.8, 
125.53, 122.51, 121.7, 120.1, 119.5, 61.8, 52.5. 
IR (neat): 2927, 1720, 1598, 1518, 1458, 1418, 1341, 1260, 1179, 1090, 902 cm-1. 
HRMS (ESI) calculated for C21H10N3O8- [M-H]- 432.0473, found 432.0466. 
 
 
9,10-[1,2]benzenoanthracen-9(10H)-ylmethanol (7): To a vial was added 1.95 g (5.94 
mmol) of 4, 70 mL of 1M HCl, and 100 mL of THF. The solution was stirred at 25 °C. 
After 1 h, ethyl acetate was added to the solution. The organic layer was extracted from the 
solution, dried with anhydrous sodium sulfate, and concentrated in vacuo to give 7 (1.68 
g, 99 % isolated yield). 
Physical Property: Pale yellow solid.31  
TLC: Rf = 0.31 (silica gel, 25% ethyl acetate/hexanes). 
1H NMR (500 MHz, (CD3)2CO) δ 7.65-7.44 (m, 6H), 7.04-6.97 (m, 6H), 5.58 (s, 1H), 5.30 
(d, 2H, J = 3.6 Hz), 4.60 (t, 1H, J = 3.6 Hz). 
13C NMR (125 MHz, (CD3)2CO) δ 147.2, 145.6, 124.71, 124.66, 123.3, 122.9, 60.0, 54.2, 
54.0. 
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IR (neat): 3308, 2962, 2918, 1579, 1458, 1261, 1071, 1035, 798, 740, 648, 629, 611, 481 
cm-1. 
HRMS (ESI) calculated for C21H17O+ [M+H]+ 285.1274, found 285.1288. 
 
 
9,10-[1,2]benzenoanthracene-9(10H)-carboxylic acid (8): To a vial, 31.9 mg (0.11 
mmol) of 7 was dissolved in acetone and heated to 50 °C. 88.6 mg (0.56 mmol) of KMnO4 
was added to the solution. Whenever the solution turned to black or brown, an additional 
88.6 mg (0.56 mmol) of KMnO4 was added to the solution. After 3 days, sodium sulfite 
solution (aq) was added to the crude mixture and then extracted with ethyl acetate. The 
combined organic layer was dried with anhydrous sodium sulfate, and concentrated in 
vacuo to yield 8 (22.4 mg, 67 % isolated yield). 
Physical Property: Pale yellow solid.32 
TLC: Rf = 0.28 (silica gel, 100% ethyl acetate). 
1H NMR (500 MHz, (CD3)2CO) δ 8.09-8.01 (m, 3H), 7.46-7.42 (m, 3H), 7.02-6.97 (m, 
6H), 5.57 (s, 1H) 
13C NMR (125 MHz, (CD3)2CO) δ 172.3, 146.4, 144.6, 125.1, 124.6, 124.6, 123.2, 62.4, 
54.2. 
IR (neat): 2925, 1712, 1458, 1448, 1386, 1261, 1213, 1171, 1085, 1032, 867, 801, 748, 
735, 703, 685, 645, 624, 609, 478 cm-1. 
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HRMS (ESI) calculated for C21H13O2- [M-H]- 297.0921, found 297.0914. 
 
 
ethyl 3-(2,7,15-trinitro-9,10-dihydro-9,10-[1,2]benzenoanthracene-9-carboxamido)-
propanoate (9): To a round bottom flask was added 213.2 mg (0.49 mmol) of 6a, 97.3 mg 
(1.23 mmol) of pyridine, and 10 mL of CH2Cl2. 140.9 mg (1.23 mmol) of MsCl was added 
to the solution at 0 °C. After 30 minutes, 188.9 mg (1.23 mmol) of beta-alanine ethyl ester 
hydrochloride and 97.3 mg (1.23 mmol) of pyridine in 10 mL of CH2Cl2 was added to the 
solution and warmed to 25 °C. After 1 h, the solution was dried in vacuo and triturated with 
ethyl acetate several times to give 9 (240 mg, 91 % isolated yield). 
Physical Property: White solid, m.p. = 304-305 ˚C. 
TLC: Rf = 0.23 (silica gel, 50% ethyl acetate/hexanes). 
1H NMR (500 MHz, (CD3)2CO) δ 8.92 (d, 3H, J = 2.2 Hz), 8.19-8.12 (bs, 1H), 8.09 (dd, 
3H, J = 8.2, 2.2 Hz), 7.90 (d, 3H, J = 8.2 Hz), 6.40 (s, 1H), 4.19 (q, 2H, J = 7.2 Hz), 4.14-
4.08 (m, 2H), 2.99 (t, 2H, J = 6.6 Hz), 1.25 (t, 3H, J = 7.2 Hz). 
13C NMR (125 MHz, (CD3)2CO) δ 171.3, 166.6, 150.5, 146.1, 144.5, 125.5, 122.4, 120.4, 
60.2, 60.0, 53.1, 35.9, 33.6, 13.6. 
IR (neat): 3301, 2924, 1722, 1668, 1521, 1342, 1261, 1203, 1031, 800 cm-1. 
HRMS (ESI) calculated for C26H20N4NaO9+ [M+Na]+ 555.1122, found 555.1127. 
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ethyl 3-(2,7,15-tris((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-9,10-dihydro-9,10-
[1,2]benzenoanthracene-9-carboxamido)propanoate (11): To a vial was charged 180 
mg (0.338 mmol) of 9, 3.6 mg (0.034 mmol) of Pd/C, 2 mL of MeOH under H2 gas. After 
24 h stirring at 25 °C, the solution was filtered and concentrated in vacuo to yield crude of 
10. To a round flask was added 10, 0.27 mL (3.38 mmol) of pyridine, and 30 mL of CH2Cl2. 
The solution was cooled and stirred for 30 minutes at 0 °C. 612.1 mg (2.37 mmol) of Fmoc-
Cl in 3 mL of CH2Cl2 was added to the solution. The crude mixture was warmed to 25 °C 
and stirred for 16 h. The solution was washed with saturated NH4Cl (aq), dried, and purified 
by column chromatography using ethyl acetate (100%) as the eluent to give 11 (310 mg, 
83 % isolated yield). 
Physical Property: White solid, m.p. = 157-158.3 ˚C. 
TLC: Rf = 0.81 (silica gel, 50% ethyl acetate/hexanes). 
1H NMR (500 MHz, CD2Cl2) δ 7.98 (s, 3H), 7.78 (d, 6H, J = 7.5 Hz), 7.59 (d, 6H, J = 6.3 
Hz), 7.39 (t, 6H, J = 7.5 Hz), 7.32-7.20 (m, 12H), 7.15 (s, 3H), 6.75 (bs, 1H), 5.28 (s, 1H), 
4.40 (d, 6H, J = 6.7 Hz), 4.19 (t, 3H, J = 6.7 Hz), 4.06 (q, 2H, J = 7.1 Hz), 3.89 (q, 2H, J = 
5.7 Hz), 2.80 (t, 2H, J = 5.7 Hz), 1.11 (t, 3H, J = 7.1 Hz). 
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13C NMR (125 MHz, CD2Cl2) δ 173.1, 168.8, 153.4, 144.3, 143.9, 141.4, 141.3, 135.2, 
127.7, 127.0, 125.0, 123.6, 119.9, 115.9, 66.7, 60.9, 60.5, 52.4, 47.1, 35.8, 34.1, 13.9. 
IR (neat): 1715, 1604, 1526, 1464, 1450, 1409, 1322, 1297, 1260, 1213, 1155, 1055, 985, 
804, 758, 737, 702, 621, 531, 501 cm-1. 
HRMS (ESI) calculated for C71H56N4NaO9+ [M+Na]+ 1131.3940, found 1131.3949. 
 
 
3-(2,7,15-tris((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-9,10-dihydro-9,10-
[1,2]benzenoanthracene-9-carboxamido)propanoic acid (12): To a vial was charged 
30.0 mg (0.027 mmol) of 11, 0.1 mL of H2SO4, 4 mL of 1,4-dioxane, and 2 mL of water. 
The solution was stirred at 80 °C. After 24 h, the solution was concentrated in vacuo and 
purified by column chromatography using ethyl acetate (100%) as the eluent to give 12 in 
quantitative yield. 
Physical Property: White solid, m.p. = 188-189 °C. 
TLC: Rf = 0.67 (silica gel, 100% ethyl acetate). 
1H NMR (500 MHz, (CD3)2SO) δ 9.83-9.53 (bs, 3H), 8.12-7.94 (bs, 4H), 7.87 (d, 6H, J = 
7.5 Hz), 7.71 (d, 6H, J = 7.5 Hz), 7.39 (t, 6H, J = 7.5 Hz), 7.30 (t, 6H, J = 7.5 Hz), 7.28-
7.07 (m, 6H), 5.36 (s, 1H), 4.39 (d, 6H, J = 6.8 Hz), 4.25 (t, 3H, J = 6.8 Hz), 3.78-3.68 (m, 
2H), 2.78-2.62 (m, 2H). 
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IR (neat): 3324, 2924, 1719, 1604, 1536, 1464, 1299, 1216, 1052, 985 cm-1. 
HRMS (ESI) calculated for C69H51N4O9- [M-H]- 1079.3662, found 1079.3630. 
 
 
General procedure for preparation of 17-19 (Solid-Phase Peptide Synthesis): To a 
SPPS reaction vessel was added 1 eq of 2-chlorotrityl chloride resin (100-200 mesh, 
substitution: 1.4 mmol/g). The resin was stirred in dry CH2Cl2 for 30 min and the solvent 
was removed by vacuum. 1.2 eq of 12 dissolved in dimethylformamide:CH2Cl2 (1:5 
volume ratio) and 5 eq of N,N-diisopropylethylamine (DIPEA) were added to the resin. 
After stirring for 10 min, an additional 1.5 eq of DIPEA was added to the resin and stirred 
overnight (12 h) at 25 °C. HPLC grade methanol was added and stirred for 20 min to cap 
the remaining reactive functional group on the resin. The solution was removed by vacuum 
and the resin was washed with CH2Cl2 (1 min, 3 times) and dimethylformamide (1 min, 3 
times). 20 % (v/v) piperidine in dimethylformamide was added to the resin, stirred for 1 h, 
and then the solution was drained. The resin was washed with dimethylformamide (1 min, 
3 times), CH2Cl2 (1 min, 3 times) and dimethylformamide (1 min, 3 times). 9.5 eq of 
corresponding Fmoc-protected amino acid (Fmoc-His(trt)-OH, Fmoc-Lys(boc)-OH, or 
Fmoc-Asn(trt)-OH) was pre-activated with 9 eq of HATU and 18 eq of DIPEA in 
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dimethylformamide. The pre-activated solution was then added to the reaction vessel and 
stirred for ~12 h overnight. The solution was removed by vacuum and the resin was washed 
with dimethylformamide (1 min, 3 times), CH2Cl2 (1 min, 3 times) and dimethylformamide 
(1 min, 3 times). 20 % (v/v) piperidine in dimethylformamide was added to the resin, stirred 
for 1 h, and then the solution was drained. The process of washing the resin and the amino 
acid coupling was repeated until the desired sequence of peptide was achieved. When the 
peptide coupling is completed, the resin was washed with dimethylformamide (1 min, 4 
times), CH2Cl2 (1 min, 4 times). The desired product was cleaved from the resin by treating 
a mixture of trifluoroacetic acid(TFA), 2,2,2-trifluoroethanol(TFE), and CH2Cl2 (9:1:1 
volume ratio) for 30 min twice. For compound 19, cleavage took 12 h. The cleavage 
solution was then collected and concentrated in vacuo. The crude mixture was dissolved in 
MilliQ water and purified by reverse-phase HPLC. Purified products (17-19) were 
analyzed by MALDI-MS and analytical reverse-phase HPLC for the purity. 
 
HPLC analysis of compound 5a-5c 
After the nitration reaction of 4, 7, and 8 with nitric acid for 24 h at 80 °C, the crude 
mixture was cooled, neutralized with K2CO3, and re-acidified with 1M HCl. Ethyl acetate 
was added to the solution and the organic layer was extracted from the solution. The 
combined organic solution was dried with anhydrous sodium sulfate, and concentrated in 
vacuo. Crude mixtures were dissolved in acetonitrile. For quantitative analysis, 9,10-
diphenylanthracene (internal standard) dissolved in acetonitrile was added to the crude 
mixture. All samples were then analyzed by reverse-phase HPLC. Solvent gradient method 
used is shown in Figure 2.5. 
59 
 
 
Figure 2.5. Solvent gradient method for HPLC analysis of 5a-5c. A: 0.1 % CF3CO2H in MilliQ 
water, B: Methanol. 
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●: 6a, ▲: 6b, ★: 6c, and ■: 9,10-diphenylanthracene (internal standard) 
 
Figure 2.6. Chromatogram of crude nitration mixture from compound 4. 
  
● 
▲ 
★ 
■ 
61 
 
 
●: 6a, ▲: 6b, ★: 6c, and ■: 9,10-diphenylanthracene (internal standard) 
 
Figure 2.7. Chromatogram of crude nitration mixture from compound 7. 
 
  
● ▲ ★ 
■ 
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●: 6a, ▲: 6b, ★: 6c, and ■: 9,10-diphenylanthracene (internal standard) 
 
Figure 2.8. Chromatogram of crude nitration mixture from compound 8. 
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●: 6a, ▲: 6b, ★: 6c, and ■: 9,10-diphenylanthracene (internal standard) 
 
Figure 2.9. Merged chromatogram of crude nitration mixtures from compound 4, 7, and 8. 
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HPLC analysis of compound 12 and 17-19 
The purified samples were dissolved in acetonitrile (for compound 12) or in MilliQ 
water (for compounds 17-19) and then analyzed by reverse-phase HPLC to confirm the 
purity of samples. Two different gradients were used as shown in Figure 2.10. (left: 
compound 12, right: compounds 17-19). 
 
 
Figure 2.10. Solvent gradient method for HPLC analysis of (left) 12, and (right) 17-19. A: 0.1 % 
CF3CO2H in MilliQ water, B: Acetonitrile. 
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Figure 2.11. Chromatogram of analytical HPLC of compound 12. 
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Figure 2.12. Chromatogram of analytical HPLC of compound 17. 
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Figure 2.13. Chromatogram of analytical HPLC of compound 18. 
  
68 
 
 
Figure 2.14. Chromatogram of analytical HPLC of compound 19. 
 
Fluorescence-quenching experiment 
Fluorescence-quenching experiments were conducted in 50 mM sodium phosphate 
buffer, pH 7.2. Inhibitor (I10) strand binding curves were obtained by adding 1 μL of 
increasing concentrations of I10 to 19 μL of 120 nM FQ-TNR 3WJ. Samples were 
incubated for 2 hours and ran in triplicate. Inhibitor strand displacement curves with 
tripycenes were obtained by incubating 14 μL of 120 nM FQ-TNR 3WJ with 1 μL of 150 
μM I10 for 2 hours a room temperature. To this complex, 1 μL of increasing concentrations 
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of triptycene was added and incubated for 2 hours. Fluoresence measurements were 
conducted in a 384-well plate and were recorded with an excitation at 495 nm and emission 
at 520 nm using 5 nm bandwidths. 
 
 
Figure 2.15. Fluorescence-quenching assay for triptycenes 17 (A), 18 (B), 19 (C), and 20* (D). 
*Triptycene 20 is an analogue of triptycene 17 lacking a linker at the C9 position.9  
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2.7 Spectra and Supplemental Information 
 
Figure 2.16. 1H NMR spectrum of 2 in CDCl3 (500 MHz). 
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Figure 2.17. 1H NMR spectrum of 3 in CDCl3 (500 MHz). 
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Figure 2.18. 13C NMR spectrum of 3 in CDCl3 (125 MHz). 
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Figure 2.19. 1H NMR spectrum of 4 in CDCl3 (500 MHz). 
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Figure 2.20. 13C NMR spectrum of 4 in CDCl3 (125 MHz). 
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Figure 2.21. 1H NMR spectrum of 5a in CDCl3 (500 MHz). 
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Figure 2.22. 13C NMR spectrum of 5a in CDCl3 (125 MHz). 
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Figure 2.23. HSQC spectrum of 5a in CDCl3. 
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Figure 2.24. HMBC spectrum of 5a in CDCl3. 
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Figure 2.25. 1H NMR spectrum of 5b in CDCl3 (500 MHz). 
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Figure 2.26. 13C NMR spectrum of 5b in CDCl3 (125 MHz). 
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Figure 2.27. HSQC spectrum of 5b in CDCl3. 
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Figure 2.28. HMBC spectrum of 5b in CDCl3. 
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Figure 2.29. 1H NMR spectrum of 5c in CDCl3 (500 MHz). 
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Figure 2.30. 13C NMR spectrum of 5c in CDCl3 (125 MHz). 
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Figure 2.31. HSQC spectrum of 5c in CDCl3. 
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Figure 2.32. HMBC spectrum of 5c in CDCl3. 
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Figure 2.33. 1H NMR spectrum of 6a in (CD3)2CO (500 MHz). 
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Figure 2.34. 13C NMR spectrum of 6a in (CD3)2CO (125 MHz). 
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Figure 2.35. HMBC spectrum of 6a in (CD3)2CO. 
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Figure 2.36. Expanded HMBC spectrum of 6a in (CD3)2CO. 
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Figure 2.37. 1H NMR spectrum of 6b in (CD3)2CO (500 MHz). 
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Figure 2.38. 13C NMR spectrum of 6b in (CD3)2CO (125 MHz). 
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Figure 2.39. 1H NMR spectrum of 6c in (CD3)2CO (500 MHz). 
96 
 
 
Figure 2.40. 13C NMR spectrum of 6c in (CD3)2CO (125 MHz). 
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Figure 2.41. 1H NMR spectrum of 7 in (CD3)2CO (500 MHz). 
98 
 
 
Figure 2.42. 13C NMR spectrum of 7 in (CD3)2CO (125 MHz). 
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Figure 2.43. 1H NMR spectrum of 8 in (CD3)2CO (500 MHz). 
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Figure 2.44. 13C NMR spectrum of 8 in (CD3)2CO (125 MHz). 
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Figure 2.45. Carbonyl carbon peak (172.3 ppm) of 8 on 13C NMR spectrum between 210 and 130 
ppm in (CD3)2CO (125 MHz). 
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Figure 2.46. 1H NMR spectrum of 9 in (CD3)2CO (500 MHz). 
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Figure 2.47. 13C NMR spectrum of 9 in (CD3)2CO (125 MHz). 
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Figure 2.48. 1H NMR spectrum of 11 in CD2Cl2 (500 MHz). 
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Figure 2.49. 13C NMR spectrum of 11 in CD2Cl2 (125 MHz). 
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Figure 2.50. 1H NMR spectrum of 12 in (CD3)2SO (500 MHz). 
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MALDI-MS analysis 
 
Figure 2.51. MALDI-MS data of compound 12. Calculated for C69H52N4NaO9
+ [M+Na]+ 
1103.363, found 1103.873.; C69H52KN4O9
+ [M+K]+ 1119.337, found 1119.863.; C69H51N4Na2O9
+ 
[M-H+2Na]+ 1125.345, found 1125.873. 
 
Figure 2.52. MALDI-MS data of compound 17. Calculated for C42H44N13O6
+ [M+H]+ 826.353, 
found 826.690.; C42H43N13NaO6
+ [M+Na]+ 848.335, found 848.679.; C42H42N13Na2O6
+ [M-
H+2Na]+ 870.317, found 870.670. 
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Figure 2.53. MALDI-MS data of compound 18. Calculated for C60H80N19O9
+ [M+H]+ 1210.638, 
found 1211.290.; C60H79N19NaO9
+ [M+Na]+ 1232.620, found 1233.284.; C60H78N19Na2O9
+ [M-
H+2Na]+ 1254.602, found 1255.278. 
 
Figure 2.54. MALDI-MS data of compound 19. Calculated for C72H98N25O15
+ [M+H]+ 1552.767, 
found 1553.231.; C72H97N25NaO15
+ [M+Na]+ 1574.749, found 1575.218.; C72H96N25Na2O15
+ [M-
H+2Na]+ 1596.731, found 1597.206. 
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Table 2.3. Crystal data and structure refinement for 5c. 
Empirical formula  C47H29N6O16Cl9  
Formula weight  1252.81  
Temperature/K  100  
Crystal system  triclinic  
Space group  P1
_
  
a  9.6450(4)Å  
b  11.5310(5)Å  
c  23.1800(9)Å  
α  92.059(2)°  
β  90.249(2)°  
γ  95.534(2)°  
Volume  2564.25(18)Å3  
Z  2  
dcalc  1.623 g/cm3  
μ  0.569 mm-1  
F(000)  1268.0  
Crystal size, mm  0.28 × 0.14 × 0.03  
2θ range for data collection      3.55 - 50.764°  
Index ranges  -11 ≤ h ≤ 11, -13 ≤ k ≤ 13, 0 ≤ l ≤ 27  
Reflections collected  81802  
Independent reflections  9384[R(int) = 0.0693]  
Data/restraints/parameters  9384/0/706  
Goodness-of-fit on F2  1.036  
Final R indexes [I>=2σ (I)]  R1 = 0.0553, wR2 = 0.1464  
Final R indexes [all data]  R1 = 0.0644, wR2 = 0.1568  
Largest diff. peak/hole  1.25/-1.10 eÅ-3  
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CHAPTER 3 : BRIDGEHEAD-SUBSTITUTED TRIPTYCENES FOR 
DISCOVERY OF NUCLEIC ACID JUNCTION BINDERS 
 
 
 
 
 
 
 
 
 
 
 
This work was done in collaboration with Sung-Eun Suh, and Dr. Stephanie A. Barros. 
 
Adapted with permission from Barros, S. A.; Yoon, I.; Suh, S.-E.; Chenoweth, D. M. Org. Lett., 
2016, 18, 2423-2426. Copyright 2016 American Chemical Society. 
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3.1 Introduction 
Nucleic acid junctions are important structural intermediates in biology.1-3 
Junctions are present in important biological processes including replication.4,5 These 
junctions also occur in viral genomes in addition to trinucleotide repeat expansions 
associated with numerous neurodegenerative diseases.6−12 These structures are also present 
in nanostructures and aptamer-based sensors.13−20 The ability to selectively modulate a 
subset of nucleic acid structures using small molecules would allow for the chemical 
control of cellular processes as well as the reprogramming of cellular events.21−37 The 
ability to differentially stabilize predefined nucleic acid structures or to reprogram and bias 
the equilibrium distribution of an ensemble of structures in a precise manner could have a 
profound impact not only in biology but also in nucleic acid nanotechnology and materials 
applications. 
 
 
Figure 3.1. Schematic of triptycene bound to a three-way junction and a key triptycene building 
block for diversification by solid-phase synthesis. 
We previously demonstrated that triptycene-based molecules can bind to three-way 
junctions (3WJs).38 Additionally, we have shown that these molecules bind to 
d(CAG)∙(CTG) repeats implicated in triplet repeat expansion diseases.39 The ability to 
112 
 
synthesize libraries of triptycene derivatives on solid supports will accelerate efforts to 
identify biologically relevant nucleic acid junction binders and provide further insight into 
the molecular recognition properties of triptycenes toward diverse junction sequences and 
topologies. To facilitate solid-phase immobilization, a point of attachment on triptycene is 
required. The bridgehead position provided a strategic location, as it is equidistant from 
the three amino groups that serve as sites of diversification (Figure 3.1). We recently 
described a synthesis for bridgehead-substituted triptycene building blocks.40 Here, we 
report a modified, more efficient synthesis by utilizing a combined Heck coupling/benzyne 
Diels-Alder strategy. The new triptycene building block was further diversified on solid 
phase with short di- and tripeptides, and the final compounds were evaluated for binding 
to a d(CAG)∙(CTG) repeat junction. We discovered new high-affinity lead compounds for 
this junction motif that will form the basis of further investigations. 
 
 
Figure 3.2. Improvement of the synthesis of triptycene intermediates in this work. 
Similar to our previous route, our synthetic plan relied on the reduction of nitrated 
triptycene, a key intermediate, to install the three key amine functional groups that serve 
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as points of future diversification (Figure 3.2). The synthetic strategy presented here 
provides a shorter synthesis with only four steps to the key intermediate compared to seven 
steps in our previous route. Additionally, this method significantly reduced total reaction 
times from 120 to 37 h and showed an improvement in overall yield (Figure 3.2). Moreover, 
the solubility of intermediates was improved. After extending the linker at the bridgehead 
via an amidation reaction in the previous route, the resulting product showed poor to 
moderate solubility in most organic solvents. However, the intermediates in this synthetic 
route have good solubility, allowing easier characterization and large-scale reactions. In 
addition, a new regioisomer 5c that has all three nitro groups facing away from the linker 
was isolated in this new synthetic route, whereas this regioisomer was not observed in the 
previous report. 
3.2 Results and Discussion 
We initiated our synthesis with a Heck reaction between 9-bromoanthracene 1 and 
methyl acrylate in the presence of palladium(II) acetate, tri-o-tolylphosphine, and 
triethylamine in a sealed tube. The Heck reaction proceeded cleanly and resulted in the 
desired product 2 in 84% yield (Scheme 3.1). Next, olefin 2 was reduced under mild 
conditions using palladium(II) acetate as the catalyst and potassium formate as the 
hydrogen source, producing 3 in 85% yield.41 The key Diels-Alder reaction with 
anthracene 3 and benzyne, generated in situ from 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate and cesium fluoride, proceeded smoothly to yield bridgehead-
substituted triptycene 4 in 95% yield. Nitration of triptycene resulted in hydrolysis of the 
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bridgehead ester and four major nitrated regioisomers that proved inseparable by standard 
chromatographic techniques. Esterification of the crude reaction greatly facilitated the 
separation of the regioisomeric mixture (5a-d) using standard silica gel column 
chromatography. The nitrated triptycene regioisomers were characterized by HMBC and 
HSQC (See Figure 3.19 ~ Figure 3.33 in section 3.7 Spectra and Supplemental 
Information). A crystal of triptycene 5d was obtained in chloroform to confirm its 
structure by X-ray crystallography (Scheme 3.1). 
Scheme 3.1. Synthesis of bridgehead-substituted triptycenes 5a−d. 
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Scheme 3.2. Synthesis of orthogonally protected building block 7 and its solid-phase synthesis. 
 
 
Next, isomer 5d was utilized in subsequent transformations that were described in 
the previous publication.40 Pd/C-catalyzed hydrogenation, Fmoc protection, and acid-
catalyzed hydrolysis of the ester were performed to yield protected triptycene acid 7 in 
78% yield over three steps. A key building block 7 was immobilized on 2-chlorotrityl 
chloride resin in preparation for solid-phase diversification (Scheme 3.2). After addition of 
triptycene and washing of the resin, the Fmoc groups on triptycene were deprotected using 
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piperidine in DMF (20% v/v) for 1 h. A decreased reaction time led to incomplete 
deprotection of all three Fmoc groups. After deprotection, the first amino acid was coupled 
onto the immobilized triptycene using HATU and DIEA. Overnight couplings were 
required for complete reaction with all three hindered aniline nitrogens. Next, subsequent 
deprotections followed by coupling of the desired amino acids were continued until the 
final sequence was obtained. The final deprotection of the amino acid side chain protecting 
groups and cleavage from resin were performed simultaneously using 9:1:1 
TFA/TFE/DCM. The resulting triptycene peptides were purified by reversed phase HPLC 
and characterized prior to evaluation of the junction binding properties. In this manuscript, 
we focused our efforts on mono-, di-, and tripeptides to maximize diversity while 
maintaining minimal molecular weight. Longer peptides can certainly be produced 
although cell permeability will be a consideration as the size increases. 
Binding of the amino acid substituted triptycenes was evaluated against a slipped-
out d(CAG)∙(CTG) repeat nucleic acid junction. Lysine and histidine containing 
triptycenes were synthesized due to their large presence in nucleic acid-protein interfacial 
interactions. Among the molecules previously tested, TripNL-(Lys)3 and TripNL-(His)3 
exhibited the highest affinity toward the junction. Several dimeric and trimeric amino acid 
substituents were synthesized for comparison (Scheme 3.3). A high-throughput assay in 
which the 3WJ was labeled with a fluorophore and a quencher was used to determine 
binding. The addition of a 10 bp oligonucleotide strand that was complementary to the 5′ 
end of the junction (I10) opened the structure, resulting in a highly fluorescent state 
(TNR*-I10), as shown in Figure 3.3. Titration of junction-stabilizing molecules resulted 
in quenching of fluorescence due to displacement of the inhibitor strand and reformation  
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Scheme 3.3. Structures of triptyene-peptides. 
 
 
 
Figure 3.3. Fluorescence-quenching experiment of triptycene peptides. 
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of the junction (TNR*-Trip). To determine if increased flexibility of the amino acid may 
play an important role in binding, glycine was coupled directly to the triptycene core 
followed by lysine or histidine. Trip-(Gly-Lys)3 (8) exhibited increased potency compared 
to that of Trip-(Lys)3, with a Kd of 90 nM, indicating that the increased flexibility may 
allow for better binding. This triptycene derivative demonstrates the highest binding 
affinity toward the TNR junction thus far. Interestingly, Trip-(Gly-His)3 (9) did not exhibit 
improved binding compared to that of Trip-(His)3. Triptycenes substituted with three 
amino acids were also synthesized using lysine, histidine, and asparagine. Trip-(His-Lys-
His)3 (10), Trip-(His-Lys-Lys)3 (11), and Trip-(His-Lys-Asn)3 (12), which only differ in 
their final amino acid, exhibited Kd values of 0.20, 0.17, and 0.39 μM, respectively. It 
should be noted that most triptycene derivatives synthesized in this work showed improved 
binding affinity compared to the most potent triptycene derivative from the previous work, 
which exhibited a Kd value of 0.27 μM. We also compared the binding affinity of Trip-
(His-Lys-Asn)3 (12) to that of TripAM-(His-Lys-Asn)3, which have the same peptide 
sequence but an amide linker at the bridgehead. They exhibited similar binding affinities 
toward the junction. Triptycenes 8-12 were also characterized using a gel shift assay, where 
the inhibitor strand was incubated with unlabeled 3WJ (see section 3.4 Material and 
Methods for experimental details). This change resulted in an electrophoretic shift that is 
consistent with a larger complex. Titration of triptycene with this complex resulted in 
reformation of the nucleic acid junction (Figure 3.12 in section 3.4 Material and 
Methods). 
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3.3 Conclusions 
In summary, we have developed a shorter, more efficient synthetic strategy toward 
a bridgehead-substituted triptycene building block. This new synthetic route is improved 
in terms of solubility, enabling large-scale reactions. Moreover, this route provides an 
interesting new regioisomer that was not observed through the previous route. A building 
block with an attachment point at the bridgehead provided rapid access to new triptycene 
peptide derivatives using solid-phase synthesis methods. The triptycene peptides were 
evaluated for nucleic acid junction binding to a triplet repeat expansion oligonucleotide 
using a fluorescence-based assay, which revealed the most potent binder to this junction to 
date. New triptycene building blocks that are amenable to solid-phase diversification 
provide a path for the discovery of new junction binders with superior properties. This new 
class of bridgehead-substituted triptycenes may allow for the generation of one-bead−one-
compound combinatorial libraries for the rapid discovery of new junction binders using 
fluorescently labeled junctions.42−44 Additionally, this new class of bridgehead-substituted 
triptycenes opens the door for the creation of pull-down probes to identify cellular targets 
in future studies. 
3.4 Material and Methods 
General information 
All commercial reagents and solvents were used as received. 9-bromoanthracene, 
potassium formate, nitric acid, Fmoc chloride, pyridine, and acetonitrile were purchased 
from Sigma-Aldrich (St. Louis, MO). Methyl acrylate, triethylamine (Et3N), tri-o-
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tolylphosphine, palladium(II) acetate, cesium fluoride, and Pd/C were purchased from 
Acros Organics. Methanol, dichloromethane (DCM), dimethylformamide (DMF) were 
purchased from Fisher Scientific (Waltham, MA). (1-[Bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium3-oxide hexafluorophosphate) (HATU) was purchased 
from Oakwood Products, Inc. (West Colombia, SC), 2-chlorotrityl chloride resin was 
purchased from Advanced ChemTech (Louisville, KY), diisopropylethylamine (DIEA), 
trifluoroacetic acid (TFA), and 2,2,2-trifluoroethanol (TFE) were purchased from Alfa 
Aesar (Ward Hill, MA), and piperidine was purchased from American Bioanalytical 
(Natick, MA). Chloroform-d, methanol-d4, dimethylsulfoxide-d6 were purchased from 
Cambridge Isotope Laboratories (Tewksbury, MA). Thin-layer chromatography was done 
using Sorbent Technologies (Norcross, GA) silica plates (250 μm thickness). Flash 
chromatography was performed on a Teledyne Isco (Lincoln, NE) CombiFlash Rf system 
using RediSep Rf silica columns. 
TNR DNA 3WJ (5’-GCGGAGCAGCCCTTGGGCAGCACCTTGGTGC-
TGCTCCGC-3’) and DNA inhibitor 10 (5’-GCTGCTCCGC-3’) were purchased from 
Integrated DNA Technologies (IDT). HPLC-purified TNR DNA 3WJ oligo modified with 
a 5’-FAM and a 3’-IowaBlack was purchased from IDT. 
1H and 13C NMR were recorded on a Bruker UNI 500 NMR at 500 and 125 MHz, 
respectively. High resolution mass spectra were obtained at the University of Pennsylvania 
Mass Spectrometry Center on a Waters LC-TOF mass spectrometer (model LCT-XE 
Premier) using electrospray ionization in positive or negative mode, depending on the 
analyte. Highperformance liquid chromatography was performed on a JASCO HPLC 
(Easton, MD) equipped with a Phenomenx (Torrance, CA) column (Analytical: Luna 5μ 
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C18(2) 100A; 250 x 4.60 mm, 5 μm Semi-prep: 5μ C18(2) 100A; 250 x 10.00 mm, 5 μm) 
using aqueous (H2O + 0.1% CF3CO2H) and organic (CH3CN) phases. Matrix-assisted laser 
desorption ionization (MALDI) mass spectra were obtained on a Bruker Ultraflex III 
MALDI-TOF-TOF mass spectrometer (Billerica, MA) using α-cyano-4-hydroxycinnamic 
acid (CHCA). Fluorescence measurements were collected on a Tecan M1000 plate reader 
(Mannedorf, Switzerland). 
 
Experimental procedures 
 
methyl-3-(anthracen-9-yl)acrylate (2)45-47: A solution of 9-bromoanthracene (1) (192 
mg, 0.746 mmol), methyl acrylate (642 mg, 7.46 mmol), Et3N (755 mg, 7.46 mmol), tri-o-
tolylphosphine (25 mg, 0.082 mmol), and Pd(OAc)2 (8.37 mg, 0.0373 mmol) in DMF (7 
mL) was heated at 120 °C in a sealed tube for 5 h. Upon cooling, the mixture was filtered 
through Celite and washed with ethyl acetate. The filtrate was extracted with ethyl acetate 
and water several times. Combined organic layers were then dried over Na2SO4. The crude 
mixture was purified by column chromatography on silica gel (5% EtOAc/hexanes) to give 
1 (164 mg, 84%). 
1H NMR (500 MHz, CDCl3) δ 8.65 (d, 1H, J = 16.3 Hz), 8.45 (s, 1H), 8.25-8.23 (m, 2H), 
8.03-8.01 (m, 2H), 7.53-7.48 (m, 4H), 6.45 (d, 1H, J = 16.3 Hz), 3.93 (s, 3H). 
122 
 
13C NMR (125 MHz, CDCl3) δ 167.0, 142.4, 131.4, 129.5, 129.4, 129.0, 128.4, 126.9, 
126.5, 125.5, 125.3, 52.1. 
IR (neat): 3051, 2949, 1719, 1635, 1435, 1265, 1170, 988, 886, 733 cm-1. 
HRMS (ESI) m/z calculated for C18H15O2+ [M+H]+ 263.1067, found 263.1074. 
 
 
methyl 3-(anthracen-9-yl)propanoate (3)45-47: To a solution of 2 (102 mg, 0.389 mmol) 
in DMF (5 mL) was added potassium formate (654 mg, 7.78 mmol) and Pd(OAc)2 (4.4 
mg, 0.02 mmol) and stirred at 60 °C for 4 h. After cooling, the mixture was filtered through 
Celite and washed with ethyl acetate. The filtrate was extracted with ethyl acetate and 
water. The combined organic layer was washed with water and brine, then dried over 
Na2SO4. The crude mixture was purified by column chromatography on silica gel (5% 
EtOAc/hexanes) to yield 3 (87.3 mg, 85%). 
1H NMR (500 MHz, CDCl3) δ 8.38 (s, 1H), 8.28 (dd, 2H, J = 8.8, 0.6 Hz), 8.02 (dd, 2H, J 
= 8.4, 0.5 Hz), 7.56-7.53 (m, 2H), 7.50-7.46 (m, 2H), 4.00-3.96 (m, 2H), 3.75 (s, 3H), 2.82-
2.79 (m, 2H). 
13C NMR (125 MHz, CDCl3) δ 173.6, 132.4, 131.7, 129.6, 129.6, 126.5, 126.1, 125.1, 
124.0, 52.0, 35.2, 23.4. 
IR (neat): 3053, 2950, 1734, 1436, 1174, 885, 732 cm-1. 
HRMS (ESI) m/z calculated for C18H17O2+ [M+H]+ 265.1223, found 265.1226. 
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methyl 3-(9,10-[1,2]benzenoanthracen-9(10H)-yl)propanoate (4)48: To a solution of 3 
(443 mg, 1.68 mmol) in acetonitrile (2.8 mL) was added CsF (764 mg, 5.03 mmol) and 2-
(trimethylsilyl)phenyl trifluoromethanesulfonate (1.0 g, 3.35 mmol) and stirred at 80 °C 
for 4 h. Upon cooling, saturated NH4Cl solution was added to the mixture and then 
extracted with dichloromethane. The combined organic layer was washed with brine and 
dried over Na2SO4. The crude mixture was purified by column chromatography on silica 
gel (5-10% EtOAc/hexanes) to yield 4 (542 mg, 95%). 
1H NMR (500 MHz, CDCl3) δ 7.40-7.30 (m, 6H), 7.04-6.95 (m, 6H), 5.34 (s, 1H), 3.85 (s, 
3H), 3.36-3.31 (m, 2H), 3.21-3.15 (m, 2H). 
13C NMR (125 MHz, CDCl3) δ 174.7, 147.0, 125.2, 125.1, 123.8, 122.1, 54.6, 53.4, 52.2, 
30.7, 22.7. 
IR (neat): 2952, 1733, 1450, 1176, 628 cm-1. 
HRMS (ESI) m/z calculated for C24H20NaO2+ [M+Na]+ 363.1356, found 363.1369. 
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methyl 3-(trinitro-9,10-[1,2]benzenoanthracen-9(10H)-yl)propanoate (5a-5d): A 
solution of 4 (424.5 mg, 1.25 mmol) in concentrated HNO3 (15 mL) was stirred at 75 °C 
overnight. The solution was cooled to room temperature, neutralized, and extracted with 
EtOAc. The organic layers were combined, washed with brine, and dried over Na2SO4. The 
crude mixture was then reesterified by stirring in methanol (50 mL) with catalytic H2SO4 
under reflux overnight. The solution was concentrated under vacuum. Water was added 
and then basified by the addition of 1M NaOH. The water was extracted with EtOAc 
immediately. The organic layer was washed with brine and dried over Na2SO4. The crude 
mixture was purified by column chromatography on silica gel (30% EtOAc/hexanes) to 
give 5a (110 mg, 19%), 5b (130 mg, 22%), 5c (37.2 mg, 6.3%), and 5d (88.3 mg, 15%). 
 
 
Physical Property: m.p. = 143-146 °C. 
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1H NMR (500 MHz, CDCl3) δ 8.32 (d, 2H, J = 1.3 Hz), 8.28 (s, 1H), 8.01 (dd, 3H, J = 8.3, 
2.2 Hz), 7.69 (d, 1H, J = 8.1 Hz), 7.62 (d, 2H, J = 8.4 Hz), 5.87 (s, 1H), 3.91 (s, 3H), 3.52 
(t, 2H, J = 7.4 Hz), 3.17 (t, 2H, J = 7.4 Hz). 
13C NMR (125 MHz, CDCl3) δ 173.4, 151.3, 150.2, 146.2, 146.1, 145.8, 145.0, 125.2, 
123.6, 122.5, 122.1, 119.4, 118.3, 54.8, 53.3, 52.7, 30.2, 22.0. 
IR (neat): 2953, 1734, 1523, 1344, 1201, 738 cm-1. 
HRMS (ESI) m/z calculated for C24H18N3NaO8+ [M+Na]+ 498.0908, found 498.0919. 
 
 
Physical Property: m.p. = 139-142 °C. 
1H NMR (500 MHz, CDCl3) δ 8.32-8.27 (m, 3H), 8.04-7.97 (m, 3H), 7.69 (d, 2H, J = 8.1 
Hz), 7.64 (d, 1H, J =8.4 Hz), 5.88 (s, 1H), 3.92 (s, 3H), 3.56 (t, 2H, J = 7.3 Hz), 3.20 (t, 
2H, J = 7.3 Hz). 
13C NMR (125 MHz, CDCl3) δ 173.4, 150.9, 150.5, 146.2, 145.8, 145.7, 145.3 125.2, 
123.6, 122.4, 122.1, 119.4, 118.1, 54.6, 53.4, 52.7, 30.2, 21.8. 
IR (neat): 3091, 2953, 2848, 1733, 1520, 1342, 1201, 736 cm-1. 
HRMS (ESI) m/z calculated for C24H18N3NaO8+ [M+Na]+ 498.0908, found 498.0919. 
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1H NMR (500 MHz, CDCl3) δ 8.32 (d, 3H, J = 2.2 Hz), 8.03 (dd, 3H, J = 8.4, 2.2 Hz), 7.60 
(d, 3H, J = 8.4 Hz), 5.79 (s, 1H), 3.92 (s, 3H), 3.48 (t, 2H, J = 7.6 Hz), 3.13 (t, 2H, J = 7.6 
Hz). 
13C NMR (125 MHz, CDCl3) δ 173.4, 149.9, 146.7, 146.4, 123.7, 122.2, 119.5, 55.2, 53.6, 
52.7, 30.5, 22.6. 
HRMS (ESI) m/z calculated for C24H16N3O8- [M-H]- 474.0943, found 474.0931. 
 
 
Physical Property: m.p. = 147-150 °C. 
1H NMR (500 MHz, CDCl3) δ 8.31 (d, 3H, J = 1.7 Hz), 8.04 (dd, 3H, J = 8.1, 1.8 Hz), 7.63 
(d, 3H, J = 8.1Hz), 5.78 (s, 1H), 3.96 (s, 3H), 3.57 (t, 2H, J = 7.3 Hz), 3.20 (t, 2H , J = 7.3 
Hz). 
13C NMR (125 MHz, CDCl3) δ 173.4, 150.5, 146.4, 125.2, 122.5, 118.3, 54.6, 53.8, 52.9, 
30.3, 21.8. 
IR (neat): 3093, 2954, 2851, 1736, 1525, 1453, 1343, 1202, 1076, 903, 823 cm-1. 
HRMS (ESI) m/z calculated for C24H18N3NaO8+ [M+Na]+ 498.0908, found 498.0910. 
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methyl 3-(2,7,15-triamino-9,10-[1,2]benzenoanthracen-9(10H)-yl)propanoate (6): To 
a solution of 5d (259 mg, 0.544 mmol) in methanol was added Pd/C (25 mg). The solution 
was purged with a H2 gas balloon and kept under H2 gas for 1 h. The mixture was filtered 
through Celite and washed with methanol. The filtrate was concentrated and purified by 
column chromatography on silica gel (5% MeOH/DCM) to give 6 (204 mg, 97%). 
1H NMR (500 MHz, MeOD) δ 7.01 (d, 3H, J = 7.7 Hz), 6.79 (d, 3H, J = 1.7 Hz), 6.33 (dd, 
3H, J = 7.7, 1.5 Hz), 4.98 (s, 1H), 3.85 (s, 3H), 3.18-3.13 (m, 4H). 
13C NMR (125 MHz, MeOD) δ 176.5, 144.6, 140.7, 124.1, 112.6, 112.2, 54.2, 53.3, 52.5, 
31.4, 23.8. 
IR (neat): 3354, 2951, 1724, 1605, 1473, 1326, 1181, 582 cm-1. 
HRMS (ESI) m/z calculated for C24H24N3O2+ [M+H]+ 386.1863, found 386.1848. 
 
 
3-(2,7,15-tris((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-9,10-[1,2]benzenoanthra-
cen-9(10H)-yl)propanoic acid (7): To a solution of 6 (116 mg, 0.301 mmol) in DCM (2.5 
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mL) was added excess pyridine. The solution was cooled to 0 °C, then added Fmoc chloride 
in DCM (2.5 mL) slowly. The solution was allowed to warm to room temperature over 
time and stirred overnight. The mixture was extracted with DCM and acidic water. The 
organic layer was washed with brine and dried over MgSO4. The crude mixture was 
purified by column chromatography on silica gel (30% EtOAc/hexanes). A solution of the 
ester (209 mg, 0.199 mmol) in dioxane (5 mL), H2O (5 mL), and catalytic H2SO4 was 
stirred at 80 °C overnight. The reaction mixture was neutralized and concentrated under 
vacuum. Water was added to the mixture and was extracted with DCM. The organic layer 
was washed with brine and dried over Na2SO4. The crude mixture was purified by column 
chromatography on silica gel (50% EtOAc/hexanes) to yield 7 (165 mg, 80%). 
Physical Property: Pale yellow solid, m.p. = 169-171 °C. 
1H NMR (500 MHz, DMSO-d6) δ 12.44 (bs, 1H), 9.58 (s, 3H), 7.89 (d, 6H, J = 7.6 Hz), 
7.72 (d, 6H, J = 7.0 Hz), 7.50 (s, 3H), 7.40 (t, 6H, J = 7.4 Hz), 7.36-7.22 (m, 9H), 7.14 (bs, 
3H), 5.37 (s, 1H), 4.44 (d, 6H, J = 6.7 Hz), 4.28 (t, 3H, J = 6.7 Hz), 3.13-2.92 (m, 4H). 
13C NMR (125 MHz, DMSO-d6) δ 174.2, 153.4, 143.7, 141.3, 140.7, 135.7, 127.6, 127.1, 
125.1, 123.2, 120.1, 114.4, 113.5, 65.5, 52.2, 50.9, 46.6, 29.2, 22.2. 
IR (neat): 3375, 3325, 3075, 2950, 1709, 1605, 1528, 1450, 1212, 738 cm-1. 
HRMS (ESI) m/z calculated for C69H52N3O8+ [M+H]+ 1038.3749, found 1038.3737. 
 
Solid Phase Synthesis 
All triptycenes were synthesized on 2-chlorotrityl chloride resin (100-200 mesh, 1.5 mmol 
substitution/g). The resin was added to a dry glass reaction vessel and swollen by stirring 
in dichloromethane (DCM) for 30 min. After swelling, the DCM was removed by vacuum 
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and Fmoc-Trip-OH (8d) was coupled to the resin. Fmoc-Trip-OH (1.5 equiv) in 1:5 
DMF:DCM and DIPEA (5 equiv) were added and stirred for 5 min. DIPEA (1.5 equiv) 
was added and the resin was stirred overnight. The solution was then drained by vacuum 
and the resin was washed thoroughly with DMF, then DCM, then DMF. The beads were 
deprotected by treatment with 20% piperidine in DMF for 1 h with stirring. The 
deprotection solution was removed by vacuum and the resin was washed thoroughly with 
DMF, DCM, then DMF. The first Fmoc-protected amino acid was then activated with 
HATU (9 equiv) in the presence of DIPEA (18 equiv) prior to addition to the reaction 
vessel and allowed to couple overnight. Subsequent deprotections and amino acid 
couplings were run as described above. Before cleavage from the resin, the terminal Fmoc 
was removed. The beads were thoroughly washed with DMF then DCM. Peptides were 
cleaved by addition of trifluoroacetic acid (TFA), 2,2,2-trifluoroethanol (TFE), and DCM 
(9:1:1). The cleavage solution was collected by vacuum and concentrated using a rotary 
evaporator. The crude residue was diluted in 1:1 (0.1% TFA/H2O:MeCN), purified by 
reverse-phase HPLC, and analyzed by MALDI-MS. 
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Figure 3.4. Crude HPLC chromatogram of triptycene 8 after cleavage from 2-chlorotrityl chloride 
resin. 
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Figure 3.5. Crude HPLC chromatogram of triptycene 9 after cleavage from 2-chlorotrityl chloride 
resin. 
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Figure 3.6. HPLC chromatogram of purified triptycene 8. 
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Figure 3.7. HPLC chromatogram of purified triptycene 9. 
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Figure 3.8. HPLC chromatogram of purified triptycene 10. 
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Figure 3.9. HPLC chromatogram of purified triptycene 11. 
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Figure 3.10. HPLC chromatogram of purified triptycene 12. 
 
Table 3.1. Calculated and observed triptycene masses. 
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Fluorescence-quenching experiment 
All experiments were conducted in 50 mM sodium phosphate buffer, pH 7.2. 
Fluorescence measurements were recorded with excitation at 495 nm and emission at 520 
nm using 5 nm bandwidths on a Tecan M1000 plate reader. Inhibitor strand displacement 
by triptycene curves were obtained by incubating 120 nM TNR DNA with 10 μM inhibitor 
10 for 2 h, followed by addition of increasing concentrations of triptycenes. Samples were 
incubated for 2 h and measured in triplicate in a 384-well plate.  
 
Figure 3.11. Fluorescence-quenching experiment plots. Displacement of I10 from TNR 3WJ by 
Trip-(Gly-Lys)3 (a), Trip-(Gly-His)3 (b), Trip-(His-Lys-His)3 (c), Trip-(His-Lys-Lys)3 (d), Trip-
(His-Lys-Asn)3 (e). An overlay of all plot is shown in (f). 
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Gel Shift Assay 
Gel shift experiments were conducted in 50 mM sodium phosphate buffer, pH 7.2. 
Triptycene titration gels were prepared by incubating TNR 3WJ (0.5 μM) with inhibitor 
strand 10 (1.5 μM) for 2 h followed by titration of triptycenes and incubation at room 
temperature for 2 h. Samples were loaded on a 20% non-denaturing polyacrylamide gel 
(19:1 monomer:bis) at 50V in 1X TBR buffer at 4 °C for 10 h. Gels were imaged by 
staining with SYBR Gold for 15 min then visualized using a BioRad GelDoc XR+ imager. 
 
 
Figure 3.12. Gel shift assay in the presence of triptycenes. TNR 3WJ was incubated with I10 
followed by titration of triptycene derivatives, Gly-Lys (a), Gly-His (b), His-Lys-His (c), His-Lys-
Lys (d), or His-Lys-Asn (e). 
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3.7 Spectra and Supplemental Information 
 
Figure 3.13. 1H NMR spectrum of 2 in CDCl3 (500 MHz). 
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Figure 3.14. 13C NMR spectrum of 2 in CDCl3 (125 MHz). 
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Figure 3.15. 1H NMR spectrum of 3 in CDCl3 (500 MHz). 
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Figure 3.16. 13C NMR spectrum of 3 in CDCl3 (125 MHz). 
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Figure 3.17. 1H NMR spectrum of 4 in CDCl3 (500 MHz). 
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Figure 3.18. 13C NMR spectrum of 4 in CDCl3 (125 MHz). 
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Figure 3.19. 1H NMR spectrum of 5a in CDCl3 (500 MHz). 
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Figure 3.20. 13C NMR spectrum of 5a in CDCl3 (125 MHz). 
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Figure 3.21. HMBC spectrum of 5a in CDCl3. Entire view (top) and expanded view (bottom). 
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Figure 3.22. HSQC spectrum of 5a in CDCl3. Entire view (top) and expanded view (bottom). 
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Figure 3.23. 1H NMR spectrum of 5b in CDCl3 (500 MHz). 
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Figure 3.24. 13C NMR spectrum of 5b in CDCl3 (125 MHz). 
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Figure 3.25. HMBC spectrum of 5b in CDCl3. Entire view (top) and expanded view (bottom). 
 
155 
 
 
 
Figure 3.26. HSQC spectrum of 5b in CDCl3. Entire view (top) and expanded view (bottom). 
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Figure 3.27. 1H NMR spectrum of 5c in CDCl3 (500 MHz). 
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Figure 3.28. 13C NMR spectrum of 5c in CDCl3 (125 MHz). 
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Figure 3.29. HMBC spectrum of 5c in CDCl3. Entire view (top) and expanded view (bottom). 
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Figure 3.30. HSQC spectrum of 5c in CDCl3. Entire view (top) and expanded view (bottom). 
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Figure 3.31. 1H NMR spectrum of 5d in CDCl3 (500 MHz). 
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Figure 3.32. 13C NMR spectrum of 5d in CDCl3 (125 MHz). 
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Figure 3.33. HMBC spectrum of 5d in CDCl3. Entire view (top) and expanded view (bottom). 
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Figure 3.34. 1H NMR spectrum of 6 in MeOD (500 MHz). 
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Figure 3.35. 13C NMR spectrum of 6 in MeOD (125 MHz). 
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Figure 3.36. 1H NMR spectrum of 7 in DMSO-d6 (500 MHz). 
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Figure 3.37. 13C NMR spectrum of 7 in DMSO-d6 (125 MHz). 
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Table 3.2. Crystal data and structure refinement for 5d. 
Empirical formula  C25H18N3O8Cl3 
Formula weight  594.77 
Temperature/K  100(1) K 
Wavelength 0.71073 Å 
Crystal system  monoclinic 
Space group  C2/c 
Cell constants:  
a  29.8039(12) Å 
b  9.4923(4) Å  
c  22.1375(9) Å 
β  120.796(2)° 
Volume  5379.8(4) Å
3
 
Z  8  
dcalc  1.469 Mg/m
3
  
Absorption coefficient  0.394 mm-1  
F(000)  2432  
Crystal size 0.25 x 0.12 x 0.10 mm
3
 
Theta range for data collection 1.59 to 25.40°  
Index ranges  -35 ≤ h ≤ 32, -11 ≤ k ≤ 11, -26 ≤ l ≤ 26  
Reflections collected  39795 
Independent reflections  4911 [R(int) = 0.0251] 
Completeness to theta = 25.40° 99.3 % 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7452 and 0.7055 
Refinement method Full-matrix least-squares on F
2
 
Data/restraints/parameters  4911 / 0 / 345 
Goodness-of-fit on F2  1.039 
Final R indices [I>2sigma(I)] R1 = 0.0335, wR2 = 0.0855 
R indices (all data) R1 = 0.0400, wR2 = 0.0897 
Largest diff. peak and hole  0.412 and -0.525 eÅ-3  
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CHAPTER 4 : MODULATION OF THE E. COLI RPOH TEMPERATURE 
SENSOR WITH TRIPTYCENE-BASED SMALL MOLECULES 
 
 
 
 
 
 
 
 
 
 
 
This work was done in collaboration with Dr. Stephanie A. Barros. 
 
Adapted with permission from Barros, S. A.; Yoon, I.; Chenoweth, D. M. Angew. Chem. Int. Ed. 
2016, 55, 8258-8261. Copyright 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
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4.1 Introduction 
Temperature is a universal stress factor for all living organisms, and a rapid 
response to temperature fluctuations is essential for cell survival. The heat shock response 
(HSR) is a cellular process characterized by the increased synthesis of a set of heat shock 
proteins (HSPs) in response to stress, such as temperature.1,2 The Escherichia coli (E. coli) 
HSR is regulated by an alternative σ factor, σ32, encoded by the rpoH gene. An increase in 
temperature from 30 ℃ to ≥ 37 ℃ results in the increased synthesis and stability of σ32, 
leading to the transcription of σ32-dependent genes involved in the HSR.3–11 Translational 
control is a common strategy for the modulation of the HSR in both eukaryotes and 
prokaryotes. Morita and co-workers have found that the σ32 mRNA secondary structure 
acts as a thermosensor, crucial for the induction of σ32, in the E. coli HSR pathway (Figure 
4.1).12-16 Intramolecular base-pairing interactions in the first 229 nucleotides control the 
translation efficiency of σ32. Analysis of a series of deletions and mutations shows the 
presence of two regulatory elements that fold into a complex structure, preventing the 
initiation of translation at low temperatures. The first regulatory element is a 15 nucleotide 
downstream box (region A) near the AUG start codon that allows for binding of the 30S 
ribosome. The second regulatory element, stem III (Figure 4.1b), blocks the downstream 
box. The AUG start codon is then blocked by nucleotides present in stem I. Base pairing 
of the start codon and the downstream box by stems I and III prevents ribosome binding at 
low temperatures. Primer-extension inhibition (toeprinting) experiments have 
demonstrated that thermal stress disrupts the RNA secondary structure, leading to ribosome 
binding and increased translation.15 These experiments directly correlated the degree of 
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ribosome binding to RNA stability.4–8 Very few small molecules have been developed for 
direct prokaryotic or eukaryotic translational control at the RNA level.17–19 Small-molecule 
probes with the ability to stabilize the σ32 mRNA secondary structure could be useful 
probes for studying the HSR pathway as well as potential antibacterial agents or adjuvants. 
 
 
Figure 4.1. a) The heat shock response in E. coli and a strategy for small molecule modulation at 
the mRNA level. b) The overall secondary structure of the 5’-end of the σ32 mRNA regulatory 
element. Important regions are shown, with the boxed area corresponding to the AUG start codon. 
Chemical and enzymatic probing of the 5’-end of the σ32 mRNA secondary 
structure reveals that the regulatory regions (regions A and B) within the RNA structure 
form a perfectly paired three-way junction (3WJ).16 Recently, we developed a new class of 
nucleic acid junction binders based on the triptycene scaffold.20–22 Herein, we report the 
first triptycene-based small molecules that are able to modulate the stability of the σ32 
mRNA. We determined the ability of these ligands to modulate the structure of σ32 RNA 
by UV thermal melting, circular dichroism (CD), and fluorescence quenching experiments. 
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Furthermore, we demonstrate the in vivo modulation of the heat shock response using a 
σ32-GFP fusion protein reporter system in E. coli. 
4.2 Results and Discussion 
We initiated our studies with a model system corresponding to the regulatory 
junction present in the rpoH mRNA (Figure 4.2). UV melting experiments were performed 
to determine the ability of Trip 1 and 2 (Figure 4.2) to stabilize the model system. In the 
absence of ligand, the RNA melted at 51.6 ℃. Thermal stabilization was observed in the 
presence of Trip 1 and 2, with ΔTm values of 11.3 and 13.7 ℃, respectively (Figure 4.2c). 
 
 
Figure 4.2. Stabilization of a model-system RNA by triptycene derivatives 1 and 2. (a) Structures 
of the triptycene derivatives Trip 1 and Trip 2. (b) The RNA oligonucleotide used as a model 
system, corresponding to a minimal sequence for junction formation. (c) UV thermal melting plots 
in the presence and absence of the triptycenes. 
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Figure 4.3. Temperature-dependent circular dichroism (CD) of model system RNA in the absence 
(a) and presence of Trip 1 (b) or Trip 2 (c). 
 
Figure 4.4. Circular dichroism (CD) of model system RNA at different concentrations of Trip 1 
(a,b) or Trip 2 (c,d). 
CD spectroscopy was also performed to investigate the interaction of Trip 1 and 2 with the 
RNA. CD spectra of the model system in the presence and absence of Trip 1 and 2 at 4 ℃ 
are consistent with A-form RNA, displaying a maximum at 266 nm, a large minimum at 
210 nm, and a smaller minimum around 240 nm (Figure 4.3). As the temperature increases 
from 4 ℃ to 80 ℃, the maximum at 266 nm decreased and the minimum at 210 nm became 
less negative. These changes are indicative of the melting of the helical segments. 
Temperature-dependent CD spectroscopy in the presence of Trip 1 and Trip 2 gave the 
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same trend, but the change was more gradual, particularly between 50 ℃ and 80 ℃ (Figure 
4.3). This result is consistent with ligand-induced stabilization as observed in the UV 
experiment. CD spectra in the presence of increasing concentrations of the triptycenes 
show slight signal changes (Figure 4.4). A more negative signal is observed at 210 nm as 
well as a decrease and slight shift at 220 nm. These changes are not consistent with 
intercalation or groove-binding modes, rather they are suggestive of native helical 
structural stabilization through a non-helix-perturbing binding event.23–25 
 
 
Figure 4.5. (a) Schematic representation of the fluorescence quenching experiment. (b) Titration 
of inhibitor 16 (I16) results in an increase in fluorescence. (c) Titration of Trip 1 or Trip 2 to the 
RNA*–I16 complex results in a decrease in fluorescence. The apparent Kd values of Trip 1 and Trip 
2 were determined to be 2.5 µM and 1.5 µM, respectively. 
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A fluorescence quenching experiment was used to further support the modulation 
of the σ32 RNA (Figure 4.5a). The oligonucleotide was labeled with a fluorophore on the 
5’-end and a quencher on the 3’-end. Once the RNA is folded, little to no fluorescence is 
observed as the fluorophore and quencher are in close proximity. Upon addition of a 16 
base pair oligonucleotide complementary to the 5’-end, an increase in fluorescence is 
observed, indicating that both ends are further apart in space owing to the formation of an 
open state (Figure 4.5b). The addition of Trip 1 and 2 to this open-state structure results in 
a decrease in fluorescence, which is consistent with reformation of the folded 3WJ state 
(Figure 4.5c). The apparent Kd values of Trip 1 and Trip 2 were determined to be 2.5 μM 
and 1.5 µM, respectively. 
Having characterized the interactions of Trip 1 and 2 with the model system by 
fluorescence quenching, we turned our attention to the full 5’-region of the σ32 mRNA(-19 
to +229). The 5’-end of the σ32 mRNA was transcribed in vitro for characterization by 
temperature-dependent UV and CD techniques. UV thermal melting experiments in the 
absence of the triptycenes showed a double inflection, indicating that portions of the 
RNAmelt at different temperatures, with the most critical structural changes occurring 
below 42 ℃. The first inflection, with an initial onset below 42 ℃, is consistent with the 
temperature-dependent translation previously observed for rpoH mRNA. In the presence 
of Trip 1 and Trip 2, thermal stabilization of the full-length σ32 mRNA (-19 to +229, Figure 
4.6) is observed. The shift in thermal stabilization is especially prominent between 30 and 
60 ℃. The CD spectra in the absence and presence of Trip 1 and 2 are consistent with an 
A-form RNA structure (Figure 4.7). The melting of the helical regions of the RNA was 
confirmed by temperature-dependent CD spectroscopy. The addition of Trip 1 or 2 resulted 
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in a more negative peak at 210 nm and a slightly lower maximum at 266 nm, which is 
indicative of a structural change in the RNA. Thermal stabilization is maximally observed 
between 40 ℃ and 50 ℃ and between 60 ℃ and 80 ℃ in the presence of the triptycenes. 
 
 
Figure 4.6. Modulation of σ32 mRNA (-19 to +229) by triptycene derivatives and targeting σ32 in 
E. coli. UV thermal melting plots in the absence and presence of Trip 1 and Trip 2. 
 
 
Figure 4.7. Temperature-dependent circular dichroism of σ32 RNA (-19 to +229) in the absence (a) 
and presence of Trip 1 (b) or Trip 2 (c). 
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Figure 4.8. (a) Targeting rpoH using a σ32–GFP fusion protein. (b) Structures of triptycenes tested. 
(c) Initial screening of triptycenes using σ32–GFP fusion assay. Relative fluorescence intensity of 
GFP control and σ32–GFP fusion at 30 °C and 42 °C in the presence of 25 μM Trip 1-5. (d) Relative 
fluorescence intensities of the GFP control and the σ32–GFP fusion protein at 30 °C and 42 °C in 
the presence and absence of Trip 1 and Trip 2. 
A reporter assay based on a σ32–GFP fusion protein was developed and used to 
monitor the responses to cellular stress in E. coli (Figure 4.8a). The rpoH gene, which 
codes for the σ32 protein, along with its promoters, was PCR-amplified from the genomic 
DNA of E. coli and inserted into a plasmid encoding GFP. Cells were grown at 30 ℃ for 
several hours in the presence or absence of various triptycene derivatives (Trip 1-5), 
followed by heat shock at 42 ℃ (Figure 4.8b-d). Cells containing the control GFP plasmid 
(no σ32) showed low relative GFP fluorescence when grown at 30 ℃ (Figure 4.8c,d). An 
increase in temperature to 42 ℃ resulted in a slight increase in fluorescence in the absence 
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and presence of triptycene derivatives using the GFP control plasmid. As expected, cells 
that contained the σ32-GFP fusion protein and were grown at 30 ℃ showed low 
fluorescence similar to the GFP control plasmid. However, those grown at 42 ℃ displayed 
a large increase in GFP fluorescence in the absence of these compounds. Upon triptycene 
addition, a decrease in fluorescence was observed to varying degrees at 42 ℃. The most 
significant decrease in fluorescence was observed in the presence of Trip 1 or Trip 2 
compared to Trip 3, 4, and 5 (Figure 4.8c). The addition of a 5 μM solution of Trip 1 or 
Trip 2 resulted in a slight decrease in the relative fluorescence intensity at 42 ℃. This 
decrease was more significant at triptycene concentrations of 25 μM. The relative 
fluorescence intensities were similar to those observed with the control GFP plasmid, 
indicating a loss of the heat shock response in the presence of both triptycenes, although 
Trip 2 appeared to be more potent. A concentration-dependent decrease in the signal at 42 
℃ was also observed (Figure 4.9). This is consistent with thermal stabilization of the 
mRNA by the triptycenes, where upon an increase in temperature, the structure is more 
folded and stable, suppressing translation of the σ32-GFP fusion protein. The increased 
translational inhibition with Trip 2 over Trip 1 could be due to a combination of affinity, 
cell permeability, or various non-specific interactions. 
Non-specific inhibition of translation was evaluated using a control GFP-only 
plasmid in the presence of Trip 1 and Trip 2. Interestingly, we observed an approximately 
fourfold increase in translation going from the GFP control plasmid at 42 ℃ to the σ32-
GFP plasmid at 42 ℃ (Figure 4.8d). This result is reflective of increased translation upon 
incorporation of the heat-shock-responsive σ32 RNA element, which promotes translation 
at higher temperatures. Furthermore, we observed a mild increase in translation upon 
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treatment with Trip 1 and 2, except in the case of σ32-GFP at 42 ℃. Polyamines have been 
shown to enhance translation in certain cases, and this effect could be the origin, although 
the effect is small.26 Bacterial growth experiments in the presence of the triptycenes 
indicate that Trip 1 and Trip 2 are moderately inhibitory at high concentrations (Figure 
4.10). Furthermore, we conducted qRT-PCR experiments to gauge the amount of 
transcriptional inhibition induced by Trip 1 and Trip 2. Overall, the mRNA levels of σ32 
 
 
Figure 4.9. Relative fluorescence intensity of GFP control and σ32-GFP fusion at 30 °C and 42 °C 
at varying concentration of Trip 1 (a) or Trip 2 (b). 
 
 
Figure 4.10. Bacterial growth at 37 °C in the absence or presence of Trip 1 or Trip 2 at different 
concentrations. 
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were not affected by Trip 1 and only moderately affected at high concentrations of Trip 2, 
indicating little inhibition of transcription or differential mRNA stabilization, except with 
high levels of Trip 2 (Figure 4.11). 
 
 
Figure 4.11. mRNA expression levels determine by qRT-PCR in the absence or presence of Trip 
1 or Trip 2 at 12.5 μM or 25 μM. Ct ratio of rpoH/rrsG (a), rpoH/arcA (b). Normalized rpoH 
expression level against rrsG (c), and arcA (d). 
 
4.3 Conclusions 
In summary, we have described triptycene-based molecules that modulate the 5’-
region of the σ32 mRNA temperature sensor from E. coli. Trip 1 and Trip 2 thermally 
stabilize a model system consisting of the critical central three-way junction that is present 
in the σ32 mRNA and responsible for regulation of the heat shock response as determined 
by UV thermal melting experiments and temperature-dependent CD spectroscopy. UV 
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thermal melting experiments on the full 5’-region of the σ32 mRNA also show thermal 
stabilization. This stabilization was corroborated by temperature-dependent CD 
spectroscopy in the presence of ligands. To determine the effect of the triptycenes on the 
heat shock response in E. coli, a σ32-GFP fusion protein assay was utilized. In the absence 
of the triptycenes, an increase in fluorescence was observed when the cells were heat-
shocked at 42 ℃, indicating σ32 protein translation. However, the addition of Trip 1 or Trip 
2 suppresses the fluorescence, which is consistent with a decrease in σ32 protein translation. 
This new class of small molecules may be useful for studying the effects of the heat shock 
response in E. coli. Furthermore, modulation of the temperature-sensing RNA regulatory 
elements in bacteria could lead to the development of novel methods for targeting 
pathogens or potentiating current antibiotics. Studies are underway to investigate these 
unique applications. 
4.4 Material and Methods 
General information 
The σ32 mRNA model system (5’-GGCACAAACGCAACACUGCAUUACCA-
UGCGGUUGUGCC-3’), Inhibitor 16 (I16) (5’-GTGTTGCATTTGTGCC-3’) and all 
other oligonucleotides were purchased from Integrated DNA Technologies (IDT). HPLC-
purified σ32 mRNA model system modified with a 5’-FAM and a 3’-IowaBlack was also 
purchased from IDT. E. coli genomic DNA was purchased from Addgene (Cambridge, 
MA USA). Restriction enzymes and T4 DNA ligase were purchased from New England 
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BioLabs. T7 RNA polymerase was purchased from Promega (Madison, WI USA). Milli-
Q (18 MΩ) water was used for all solutions (Millipore; Billerica, MA, USA). 
Ultraviolet absorption spectroscopy and thermal denaturation experiments were 
performed on a JASCO V-650 spectrophotometer (JASCO Analytical Instruments; Easton, 
MD, USA) equipped with a JASCO PC-734R multichannel Peltier using quartz cells with 
1 cm path lengths. Circular dichroism experiments were performed on a JASCO J-1500 
CD Spectrometer (Easton, MD, USA) using a 0.1 cm path length quartz cuvette. 
Fluorescence measurements were collected on a Tecan M1000 plate reader (Mannedorf, 
Switzerland). Polymerase chain reaction (PCR) was run on a BioRad C1000 Touch 
Thermocycler. 
 
Experimental procedures 
Synthesis: 
Trip 1 and Trip 2 were synthesized according to previously described methods.21 
 
Synthesis of rpoH mRNA -19 to +229: 
Plasmid pRSET-EmGFP (HA EmGFP ABC2 V94F) was used for cloning into the 
XbaI and EcoRI restriction sites. The rpoH (-19 to 229) gene was obtained by PCR 
amplification from genomic DNA from E. coli K-12. The forward and reverse primers used 
were 5’-GATCTAGAATCGATTGAGAGGATTTGAATG-3’ and 5’-GAGAATTCCC-
GCCTGTGGCAGGCCATAGC-3’, respectively. The pRSET-EmGFP plasmid was 
digested with XbaI and EcoRI then gel purified to isolate the linear vector. The σ32 (-19 to 
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229) PCR product was also digested and inserted into the plasmid using T4 DNA ligase. 
The resulting plasmid was verified by DNA sequencing using a T7 primer. 
The DNA template was prepared for transcription by linearization with EcoRI then 
gel purified. The RNA was transcribed in vitro by T7 RNA polymerase (Promega). In vitro 
transcription reactions were set up using the protocol supplied by Promega with 1X 
transcription buffer, 10 mM DTT, 0.5 mM each rNTP, and 2-5 μg DNA. 
 
UV Thermal Denaturation: 
Model system RNA was suspended at 1 μM in 10 mM sodium phosphate buffer, 
pH 7.2 and annealed by heating to 90°C for 5 min, cooled to room temperature slowly, 
then to 4 °C. Samples were incubated for 1 hour at room temperature with 1 μL of ligand 
at a final concentration of 2 μM. σ32 RNA (-19 to +229) was suspended at 0.25 μM in 10 
mM sodium phosphate buffer, pH 7.2 and annealed by heating to 65 °C for 5 min, cooled 
to room temperature slowly, then to 4 °C. Samples were incubated for 1 hour at room 
temperature with 1 μL of ligand at a final concentration of 2.5 μM. Denaturation was 
recorded at 260 nm from 20 °C to 90 °C with a heating rate of 0.5 °C min-1. 
 
Fluorescence Quenching Experiments: 
All binding experiments were conducted in 50 mM sodium phosphate buffer, pH 
7.2. Fluorescence measurements were recorded with excitation at 495 nm and emission at 
520 nm using 5 nm bandwidths. Inhibitor strand binding curves were obtained by adding 
1 μL of increasing concentrations of inhibitor strand to 19 μL of 120 nM RNA. Samples 
were incubated for 2 hours and ran in triplicate in a 384-well plate. Inhibitor strand 
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displacement curves were obtained by incubating 120 nM RNA with 1.4 μM inhibitor 16 
for 2 hours, followed by addition of increasing concentrations of Trip 1 or Trip 2. Samples 
were incubated for 2 hours and measured in triplicate. 
 
Circular Dichroism: 
Model system RNA was suspended at 5 μM in 10 mM sodium phosphate buffer, 
pH 7.2 and annealed by heating to 90°C for 5 min, cooled to room temperature slowly, 
then to 4 °C. Spectra were measured every 1 nm between 350 nm and 200 nm with a 16 s 
averaging time. Samples containing ligand were incubated with Trip 1 or Trip 2 (10 μM) 
at room temperature for 1 hour. Samples were incubated at each temperature for 20 minutes 
prior to scan. All CD spectra were buffer corrected and converted to molar ellipticity. 
σ32 mRNA (-19 to +229) was suspended at 0.5 μM in 10 mM sodium phosphate 
buffer, pH 7.2 and annealed by heating to 65°C for 5 min, cooled to room temperature 
slowly, then to 4 °C. Spectra were measured every 1 nm between 350 nm and 200 nm with 
a 16 s averaging time. Samples containing ligand were incubated with Trip 1 or Trip 2 (5 
μM) at room temperature for 1 hour. Samples were incubated at each temperature for 20 
minutes prior to scan All CD spectra were buffer corrected and converted to molar 
ellipticity. 
 
σ32-EmGFP Plasmid Construction: 
Plasmid pRSET-EmGFP (HA EmGFP ABC2 V94F) was used for cloning into the 
XbaI and EcoRI restriction sites. The rpoH gene was obtained by PCR amplification from 
genomic DNA from E. coli K-12. This included four rpoH promoters (p2, p3, p4, and p5). 
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The forward and reverse primers used were 5’-GATCTAGAGAACTTGTGGAT-
AAAATCACG-3’ and 5’-GAGAATTCGGATCCTTACGCTTCAATGGCAGCAC-3’, 
respectively. The pRSET-EmGFP plasmid was digested with XbaI and EcoRI then gel 
purified to isolate the linear vector. The rpoH PCR product was also digested and inserted 
into the plasmid using T4 DNA ligase. The resulting plasmid was verified by DNA 
sequencing using a T7 primer. 
 
σ32-EmGFP Assay: 
E. coli DH5α cells transformed with the σ32-EmGFP plasmid were grown overnight 
at 30 °C in Luria broth (LB) supplemented with 50 μg/mL ampicillin. Overnight cultures 
were diluted 1:100 in LB. Triptycenes were added at a final concentration of 25 μM. 
Samples were allowed to grow at 30 °C for 3 hours. Cultures were kept at 30 °C or heat 
shocked at 42 °C for 18 hours. Optical density was measured at 600 nm. Fluorescence was 
measured by excitation at 486 nm and emission at 535 nm. Measurements were made in 
triplicate for each sample. The raw fluorescence intensity was divided by the optical 
density at 600 nm, which was then normalized. 
 
qRT-PCR Experiment: 
E. coli DH5α cells transformed with the σ32-EmGFP plasmid were grown as 
described in σ32-EmGFP Assay. Triptycenes were added at a final concentration of 25 or 
12.5 μM. Samples were allowed to grow at 30 °C for 3 hours. Cultures were then kept at 
30 °C for 18 hours. Total RNA from E. coli was extracted and purified using RNAprotect 
Bacteria Reagent (QIAGEN, catalog #: 76506) and RNeasy Mini Kit (QIAGEN, catalog 
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#: 74104). The user manual provided by QIAGEN was followed. The expression was 
quantified in quadruplicate by qRT-PCR using Custom TaqManTM Gene Expression 
Assays (Applied Biosystems by Life Technologies, Foster City, CA, USA) at the 
University of Pennsylvania Perelman School of Medicine Molecular Profiling Core. The 
reverse transcription reaction was carried out with High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) in 100 μL containing 1.0 μg RNA in 30.0 μL 
nuclease free water, 4 μL of 25X (100 mM) dNTPs, 5 μL of multiscribe reverse 
transcriptase (50 U/μL), 10 μL of 10X reverse transcription buffer, 10 μL 10X random 
primer. For synthesis of cDNA, the reaction mixtures were incubated at 25° C for 10 min, 
at 37 °C for 120 min, at 85 °C for 5 min and then held at 4 °C. Then, 4.5 μL of 1:5 diluted 
cDNA solution was amplified using 5.0 μL TaqMan 2 × Fast Universal PCR Master Mix 
with no AmpErase UNG (Applied Biosystems), 0.5 μL of assay in a final volume of 10.0 
μl. Quantitative PCR was run on a QuantStudio 12K Flex Real-Time PCR system (Applied 
Biosystems) and the reaction mixtures were incubated at 95 °C for 10 min, followed by 40 
cycles of 95 °C for 15 s and 60 °C for 1 min. 
The cycle threshold (Ct) values were calculated with QuanStudio Software version 
1.2.2 (Applied Biosystems). The mRNA levels of rpoH were normalized to two 
housekeeping genes, rrsG (16S ribosomal RNA of rrnG operon) and arcA (response 
regulator in two-component regulatory system with ArcB or CpxA), using the methods 
described below. 
Method A: Ct (rpoH) / Ct (rrsG or arcA) 
Method B27: ΔCt1 = Ct (rpoH_Trip 1 or 2) – Ct (rrsG or arcA_Trip 1 or 2) 
ΔCt2 = Ct (rpoH_No compound) – Ct (rrsG or arcA_No compound) 
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ΔΔCt = Ct1 – Ct2 
Normalized rpoH gene expression level = 2ΔΔCt 
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CHAPTER 5 : CONCLUSION AND FUTURE DIRECTIONS 
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In this dissertation, we described syntheses of 9-substituted triptycene scaffolds for 
a rapid diversification through solid-phase synthesis. In the first synthetic strategy, we 
utilized the amidation reaction between carboxylic acid at C9 position and β-alanine ethyl 
ester to install the amide linker at the desired position. Because of a sterically hindered and 
geometrically fixed tertiary carboxylic acid at the bridgehead carbon, only MsCl activation 
strategy was successful to form a key amide bond. In the second synthesis, we applied the 
heck coupling reaction to introduce a linker to a triptycene scaffold. Compared to the 
previous synthesis, this new synthetic route reduced the number of steps and hours of 
reaction time as well as improved the solubilities of intermediates, enabling large-scale 
reactions. 
These new 9-substituted triptycene building blocks were then attached to a 2-
chlorotrityl chloride resin, which is compatible with Fmoc chemistry, and diversified on 
the resin. This immobilization technique enabled a fast diversification and an easy 
purification of triptycene derivatives. In our investigations, several mono-, di-, and tri-
peptide triptycenes were synthesized and evaluated their binding affinities towards a 
d(CAG)∙(CTG) trinucleotide repeat junction. The most powerful binder exhibited Kd value 
of 90 nM. These new synthetic strategies allows for rapid and efficient access to triptycene 
building blocks that are amenable to solid-phase diversification. This would provide a path 
for the discovery of new junction binders with superior properties through a rapid screening 
of triptycene-based small molecules. Moreover, 9-substitued triptycenes may enable the 
generation of one-bead-one-compound combinatorial libraries, the generation of triptycene 
microarrays and the creation of pull-down probes to identify cellular targets in future 
studies. 
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In Chapter 4, we demonstrated the modulation of three-way junction in σ32 mRNA 
temperature sensor in E. coli using triptycene-based small molecules. We investigated the 
thermal stabilization of a model three-way junction system by triptycenes from UV thermal 
melting experiments and temperature-dependent CD spectroscopy. To examine the 
modulation of heat shock response by triptycenes in vivo, a σ32-GFP fusion protein assay 
was utilized. The addition of triptycene derivatives decreased the fluorescence intensity, 
which is consistent with a decrease in σ32 protein translation. Furthermore, we conducted 
qRT-PCR experiments to monitor the level of transcription in the presence of triptycene 
derivatives. Novel methods for targeting pathogens or potentiating current antibiotics could 
be developed by a modulation of nucleic acid with triptycene-based small molecules. 
A synthesis of new triptycene-based small molecules with different substitution 
patterns is undergoing. Based on the modelling study, we reasoned that substitution 
patterns of the benzene rings could change the mode of interactions between the junctions 
and triptycene ligands. The influence of substitution patterns on molecular recognition will 
be investigated with alpha-position substituted triptycenes. 
Crystallography and AFM imaging studies are also undergoing in our research 
group to visualize the interaction between triptycenes and three-way junctions. This would 
allow us to expand our knowledge on ligand-nucleic acid interactions and to design more 
potent junction binders based on the structural information. 
